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ABSTRACT

Tapp, Katherine N. Ph.D., Purdue University, December 2014. Evaluation of Yttrium-90
Positron Emission Dosimetry. Major Professor: Gary Hutchins

Purpose: Radioembolization is a novel treatment which utilizes the liver’s unique dual
system blood supply to trap yttrium-90 (90Y) microspheres in microvasculature near liver
tumors. Radioembolization dose planning and dosimetry are based on crude, inaccurate
assumptions due to the lack of knowledge of patient specific 90Y microsphere
distribution. In recent years, the very small 3.1867e-5 internal pair production decay
branch of 90Y has been shown to allow for positron emission tomography (PET) imaging
following radioembolization. This work explores the accuracy and limitation of 90Y PET
imaging due to the extremely low signal to noise (SNR) ratio associated with 90Y and
verifies the accuracy of using these PET images for 3-dimensional (3D) dosimetry.
Material and Methods: PET acquisitions of a phantom containing 90Y filled cylindrical
inserts were acquired to determine quantitative accuracy of the PET images to measure
90

Y activity. Numerous reconstruction algorithms were used to determine the optimal

protocol to balance image noise and accuracy. A GATE model of the PET scanner was
used to evaluate the origin of prompt signal and random noise coincidence counts in these
PET acquisitions. PET images were converted to dose maps using standard S-kernel
convolution. Polymer gel dosimetry was used to validate the 3D dose map results.

xiv
Furthermore, PET, with associated CT images, were used as input data into MC
simulations to model dose rates surrounding patients for future patient release studies. A
Siemens® Biograph 64 TruePoint PET/CT was used for all acquisitions and
reconstructions.
Results: The phantom study determined Siemens® OSEM-PSF algorithm, known as
TrueX, with 2 iterations and 14 subsets had the optimal balance of noise and accuracy.
Using this reconstruction algorithm, the PET images were found to accurately measure
activity and calculated dose within 10% when 90Y concentration was above the minimum
detectable concentrations (MDC) of 1 MBq/ml. However, this reconstruction algorithm
was shown to have a positive bias in areas where concentration was below the MDC due
to truncation of negative sinogram bin values caused by statistical noise in the random
correction. Polymer gel dosimetry verified the accuracy of PET dose maps but also
identified a limitation in cases of highly gradient distributions due to the PET spatial
resolution spreading of measured activity. Additionally, external dose rates were found
to be accurately predicted through use of 90Y PET/CT images as inputs into a MC
simulation.
Conclusion: Research in 90Y PET/CT has quickly been expanding over recent years as a
feasible method to provide liver distribution of 90Y following radioembolization. This
study demonstrates the accuracy and limitations of the use of these 90Y PET/CT images
in patient specific qualitative dosimetry.
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CHAPTER 1. INTRODUCTION

1.1

Introduction

Hepatocellular carcinoma (HCC) is the sixth most prevalent type of cancer and is the
third leading cause of cancer-related deaths worldwide(1). It is estimated that there are 1
million cases of HCC worldwide and its incidence is expected to increase due to growing
Hepatitis C prevalence and HCC’s link to Hepatitis C induced cirrhosis(2). Surgical
resection, liver transplantation, and percutaneous ablation are highly effective treatment
options for patients in early stages of the disease but these treatment options are limited
to 25 to 40% of patients in the US who do not have advanced stage HCC at the time of
diagnosis(3). In the past, a majority of the patients with advanced disease had limited
therapeutic treatment options because HCC is multidrug and radiation resistant compared
to the surrounding normal liver parenchyma tissue(4).
Radioembolization is a novel form of brachytherapy in which embolic microspheres
loaded with 90Y are administered via an intraarterial injection. For the treatment of liver
tumors, including HCC, 90Y microspheres are administered into the hepatic artery and
travel downstream in the vasculature where they become trapped in the liver capillary
beds due to their 20 – 30 μm diameter(5).

90

Y is used as the therapeutic radionuclide

because it is almost a pure beta emitter, which is able to irradiate tissues over a short
average distance of 2.5 mm (11 mm maximum) while sparing the remaining liver and
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extra-hepatic tissues. The goal of the treatment is for the microspheres to become lodged
within the tumor vasculature, where they provide a large absorbed dose to the tumor
volume leading to cell death and destruction of essential tumor vascular, while
maintaining the dose to normal surrounding liver tissue below cytotoxic levels. This
therapeutic objective is normally achieved because to the hepatic artery supplies
approximately 80-100% of the blood flow to the tumor, while supplying only 20-30% of
blood flow to the normal healthy liver tissue(6).
Radioembolization currently is considered a late stage treatment and used only after
patients have exhausted all other standard treatment options. The treatment goals are to
increase time to tumor progression, extend overall survival, and improving quality of life.
Radioembolization has been shown to increase patient median survival compared to
historical treatment controls, with one 80 patient study demonstrating an increase from
244 and 64 days to 649 and 302 days for Okuda I and II patients, respectively(7).
Additionally, radioembolization has been used successfully as a bridge to transplantation
therapy, with one 35 patient study demonstrating 65% of patients were downstaged to
transplantation, resection, or radiofrequency ablation(8).
Radioembolization can result in severe complications due to radiation damage to healthy
liver. Radioembolization induced liver disease (ReILD)occurs if too much healthy tissue
receives a high level of radiation exposure and liver function is destroyed, sometimes
leading to death(5). ReILD has been difficult to classify, but one study defines it as
jaundice and ascites appearing 1 to 2 months after treatment without tumor progression or
bile duct occlusion and may lead to death(9). Although ReILD is generally found only in
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patients with cirrhosis or those who previously had chemotherapy, there is currently no
method to predict which of these treatments may lead to ReILD. Unfortunately, there is
currently no clinical method to predict which treatments will be a success and which ones
may lead to complications.

1.2
1.2.1

Background
HCC Background

In many cases, HCC arises from an underlying liver disease, such as Hepatitis B or C
(HBV/HCV) and liver cirrhosis. Approximately 2 billion individuals have HBV
worldwide, which is believed to lead to 96,000 to 160,000 HCC related deaths
annually(10). The majority of HCC cases are believed to be linked to HCV induced liver
cirrhosis(11). Heavy alcohol consumption, which may also lead to cirrhosis, is a
significant risk factor for HCC. However, not all cases are associated with cirrhosis, with
incidence in non-cirrhosis livers found to be between 10-50% in varying studies(12).
HCC is a complex disease leading to large variations in morphology related to size and if
surrounding liver is cirrhotic. In cirrhotic livers, small tumors may be well demarcated
with a fibrous capsule and advanced tumors are generally expansive and accompanied by
intrahepatic metastases. In non-cirrhotic livers, HCC tumors generally grow faster and
larger, potentially infiltrating both liver lobes(12). The large variations in HCC tumor
types, with differences in liver function reserve due to presence or lack of cirrhosis, make
it difficult to model HCC treatment outcomes in patient groups.
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HCC is the primary cancer in the liver, which is the second largest organs in the body.
Typical liver mass in a healthy adult is between 1.2 and 1.7 kg(13). Its volume is divided
into two lobes, with the right lobe generally containing about 70% of liver mass and the
left lobe containing the remaining 30%(14). The liver is made up of functional
hexagonally shaped subunits known as lobules. The liver blood supply is delivered by
two pathways, the portal vein and hepatic artery. The portal vein supplies the majority of
the blood to, approximately 20-30%, to the healthy liver tissue. Blood travels through
branches of the portal vein and hepatic artery the central vein and then complex network
of hepatic sinusoids found in each lobule. Sinusoids make up the capillary network of the
liver as they are the small blood vessels found between plates of hepatocytes which are
one or two cells thick(15). Blood travels through the sinusoids towards the periphery of
the acinus, which is connected to the terminal hepatic venules. The venules progressively
turn into larger hepatic vein branches as the blood leaves the liver through the inferior
vena cava(16).

1.2.2
90

Yttrium-90 Microspheres

Y major decay pathway (>99.98%) is via a high energy - decay to the stable ground

state of 90Zr with a maximum energy of 2.28 MeV. This - particle is the principle
radiation of concern for the internal dosimetry of the patient as it irradiates tissue over its
maximum range of 11 mm. The half-life of 90Y is 64.053 ± 0.020 hrs(17).
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Figure 1.1Yttrium-90 Decay Scheme
The remaining approximate 0.01% of decay occur via - emission to an excited 0+ state
of 90Zr, which immediately decays through internal pair production, internal conversion,
or two photon de-excitation (figure 1.1). The internal pair production was first predicted
by Ford and verified by Johnson et al. in 1955, where the probability of pair production
per decay was observed to be (2 ± 1)e-4. This branching ratio as changed several times
throughout the years as more sensitive detection equipment became available. Most
recently, Selwyn et al. found it to be (3.1857±0.047)e-5 using high purity germanium
detectors measuring the annihilation photon coincidence(18).
Currently, there are only two different manufacured types of 90Y microspheres available
in North America, glass micropsheres from TheraSphere® and resin microshpheres from
SIR-Sphere®. Although similar in use, there are slight differences between the two.
TheraSpheres are glass spheres with the Y incorporated inside its matrix, with the 90Y
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being created from 89Y through reactor based neutron activition. TheraSpheres® have a
diameter of 20 to 30 μm and an average activity of 2500 Bq per sphere. For SIRSpheres®, the 90Y is encapsulated in resin surrounding the microsphere and have an
average diameter of 35 μm and activity of 50 Bq per sphere(19). Due to the difference in
activity, substantially more particles are injected with SIR-Spheres® than TheraSpheres®
during treatment. TheraSpheres® was the only microsphere used this work since it is the
most common treatment used in recent years at Indiana University Health University
Hosptital in Indianapolis, Indiana. However, imaging and dosimetry techniques, for all
but impurity photons background noise discussed in chapter 3, should be directly
applicable to SIR-Sphere® treatments as well.

1.3

Clinical Procedure

When radioembolization was first introduced, it had severe limitations due to some
treatments having pulmonary shunting leading to pulmonary fibrosis and regional
perfusion leading to gastrointestinal (GI) toxicity. To screen out patients who could have
these complications, patients must now undergo a planning arteriogram to determine the
amount of microspheres which leave the liver due to shunting. During this procedure, the
Interventional Radiologist (IR) first performs targeted hepatic arterial catheterization
during a planning angiogram to limit shunting. The IR then injects 99mTc
macroaggregated albumun (MAA) particles as a microsphere surrogate allowing for a
diagnostic whole body gamma camera imaging or single photon emission computed
tomography (SPECT) to predict the fraction of microspheres which will end up in the
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lung due to shunting or perfusion into the GI tract. The lung shunt fraction (LSF) is
determined based on the counts found in the lung (Clung) and liver (Cliver),
Equation 1.1

 


.
  

The 99mTc MAA is used as a surrogate to predict extrahepatic distribution due to its
similar size to the microspheres. The MAA particles are delivered by the IR through a
catheter which is guided into the hepatic artery from the femoral artery under
fluoroscopy. A patient is excluded from treatment if the 99mTc-MAA predicts a potential
shunt resulting in greater than 30 Gy to the lungs or any shunting to the GI tract that
cannot be corrected by catheter embolization techniques(5). Additional treatment
contradictions include excessive tumor burden with limited hepatic reserve, elevated total
bilirubin level (> 2mg/dl) in the absence of a revisable cause, and compromised portal
vein without the ability to conduct selective radioembolization(20).
Approximately 2 weeks after the planning angiogram, the 90Y microspheres are delivered
through a catheter which is placed in the similar location and manner as the MAA
particles. The IR injects the microspheres using a manufacturer designed administration
apparatus which is designed to provide shielding from the 90Y dose vial.
In current clinical practice, there are three common methods currently used to determine
activity to be delivered. First, the simpliest is the non-compartmental Medical Internal
Radiation Dose (MIRD) method, which is described by the following equation:
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Equation 1.2



;

where A is injected activity of 90Y in GBq, M is mass of the treated volume in kg whether
it be the segment, lobe or whole liver, and D is the uniform dose in Gy to the treated
volume. This is the most commonly used method for TheraSphere® treatments, where
the recommended dose to the entire volume is 80 to 120 Gy(5).
There are two prescribed activity determinations described in the SIR-sphere® package
insert(21). First is the body surface area method (BSA), where activity is calculated
based on the patients BSA as shown:
Equation 1.3



 

    

Equation 1.4




      


where A is again activity in GBq, h is height of the patient in m, w is weight in kg, and

 and  are tumor and treated liver volume, respectively. The second SIR-sphere
method is the empiric method, which is based on the size of the tumor volume as shown
in table 1.1.
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Table 1.1Empirical dosimetry method for 90Y activity determination commonly used in
SIRsphere® treatments
Tumor Involvement in the Liver
Prescribed Activity
25%
2 GBq
25 – 50 %
2.5 GBq
> 50%
3 GBq

Following the treatment, it is recommended a post procedural imaging scan is
recommended to qualitatively evaluate 90Y distribution to ensure minimal presence of
extra-hepatic shunting. In many institutions, this is completed through SPECT imaging
of the - produced Bremsstrahlung photons. PET imaging, as described below, has also
started to be used in a few intuitions to provide this post procedural distribution map.

1.4

Clinical Dosimetry

Radioembolization is a unique form of radiotherapy. The limited photon emission which
makes 90Y advantageous for treatment, makes it clinically difficult to determine the
source distribution on a patient specific basis. Therefore, unlike sealed source
brachytherapy and external radiotherapy, intra-organ dosimetry is generally not
determined on a patient basis. Without a known source distribution, gross assumptions
are necessary to determine patient dosimetry and large errors are expected in all of the
following clinically used dosimetry methods currently being used.
The first clinically used dosimetry method is based on the non-compartmental MIRD
model. The non-compartmental model assumes the microspheres are deposited
homogeneously, and therefore provides a uniform dose to the treated lobe. The dose is
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then easily calculated by dividing the total 90Y energy released by the treated lobe mass,
as described by the following equation,
Equation 1.5



   ,


where k is conversion factor,  is cumulative activity, M is mass of the treated volume,
and E is average energy per disintegration. Cumulative activity is determined as
described below:
Equation 1.6



 


    ,

where, A is the injected activity, and S is lung shunt percent fraction. Time is integrated
to infinity because the microspheres become permanently lodged and are nonbiodegradable. Assuming activity in GBq and mass is in Kg, k is generally rounded to 50
and the equation simplifies to:
Equation 1.7



   



The assumption that the microspheres deposit uniformly used in this non-compartmental
model is known to be false. As described previously, microsphere deposition is generally
preferentially delivered to the tumor volume because of tumor hypervascularity and
higher proportion of hepatic artery blood supply as compared to normal liver tissue(22).
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Therefore, is method generally underestimates tumor and overestimate normal tissue
doses. Additionally, it fails to provide any warning when preferential tumor deposition
does not occur due to unique patient vasculature or a bad catheter position during
administration. However, since there has not been a proven way to determine patient
specific 90Y distribution, this currently is the most commonly used dosimetric method
with TheraSphere® treatments.
The second dosimetry method, known as the compartmental MIRD method or partition
method, tries to estimate the difference in tumor and normal tissue microsphere
distribution by defining them as two separate compartments. The difference in
distribution is then modeled based on a tumor to normal tissue dose ratio (TNR), which
uses the mass of the tumor (Mt) and normal tissue in the treatment volume (Mn) and
activity (A) found in the pretreatment 99Tc-MAA SPECT as shown in the following
equation,
Equation 1.8

 


 .


Dose to the tumor and normal treated volume tissue is then determined from:
Equation 1.9



      ,
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Equation 1.10



  
  .

This corrects for the difference in uptake between tumor and normal tissue assuming
99

Tc-MAA accurately predicts 90Y microsphere distribution. However, there is only a

few studies which have looked into the correlation between the distributions and results
are varied. It is believed the distributions may be mismatched due to differences in
catheter position, injection techniques, particle size, flow during the injection,
progression of the disease between injections, and differences in imaging techniques(23).
The recommended post-procedural SPECT imaging is currently generally used to
determine qualitative distribution to find gross problems such as extra-hepatic shunting.
Research studies have emerged to try to assess the feasibility of using SPECT images to
determine patient specific 90Y dose distributions(24, 25), but clinical quantitative images
for dosimetric use have been difficult to generate due to the continuous energy spectrum
and low spatial resolution associated with bremsstrahlung SPECT.

1.5

90

Y Positron Emission Tomography

In 2004, Nickles et al. demonstrated 90Y positron emission tomography (PET) imaging is
possible due to the internal pair production pathway(26). This study demonstrated 90Y
activity can be quantified from PET through imaging a Derenzo phantom using a bismuth
germinate (BGO) crystal micro-PET scanner. In 2009, Llommel et al. published the first
patient PET image using a Time of Flight (TOF) with lutetium-yttrium-oxyorthosilicate
(LYSO) crystals(27). Following publication of this image, several studies have
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demonstrated the feasibility of using PET/CT images for quantitative images(28-31).
Many studies have even shown feasibility of using these PET images for patient specific
dosimetry following radioembolization(32-34).
Due to the low positron emission rate and bremsstrahlung photon emission,

90

Y creates

an extremely low signal to noise ratio (SNR). This low SNR make 90Y a non-ideal PET
radionuclide. Acquisition and reconstruction techniques are not expected to be the same
as with other radionuclides, like 18F. Even though many groups have shown 90Y PET
imaging feasibility, little work has been completed to validate the dose maps or analyze
the influences PET acquisition and reconstruction methods have on accuracy. Once the
90

Y PET images are validated, it is believed they could be used to predict treatment

response and normal liver complications such as ReILD, enhancing the efficiency and
safety of SIRT. Therefore, the aims of this study are to provide evaluation and validation
of 90Y PET imaging and are expressed below:
1) Evaluate the effects various reconstructions algorithms have on the accuracy
and limitations of 90Y PET/CT imaging.
2) Determine origin of 90Y PET coincident count signal and noise to support
appropriate reconstruction techniques.
3) Evaluate the effect of positive bias observed in 90Y PET/CT using standard
clinical iterative algorithm techniques for reconstruction following sinogram
truncation.
4) Validate 90Y PET/CT dose maps created using a standard S-kernel using gel
dosimetry.
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5) Use PET/CT 90Y activity distribution maps to verify line source assumption
used in patient release surveys.
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CHAPTER 2. ACCURACY AND LIMITATIONS OF VARIOUS PET
RECONSTRUCTION TECHNIQUES FOR 90Y IMAGING

2.1
2.1.1

Introduction
PET Acquisition

PET images are created by detection of the two 511 keV photons produced by
positronium (positron-electron pair) annihilation. The annihilation photons are detected
by scintillation crystals, which convert photon iteraction into light. The light signal is
then multiplied in coupled photomultiplier tubes (PMT) attached to a block of crystals.
The distribution of the light across the PMTs enables the determination of the location of
the incident photon. The electronic signal produced by the PMT is proportional to the
energy deposited during the photons interaction with the crystal.
The detection of one photon is often described as a single event. For a coincidence event
to be recorded, 2 single events must be detected within a short time window, generally
around 4-6 ns. These coincident events are known as a prompt events and are recorded
as lines of response (LOR) defined by pairs of detetor elements. When the coincedent
event represents the detection of both photons from a single positron annihilation which
had no previous interaction, such as compton scattering, they are called true events
(trues). The LOR associated with a true event will overlap with location of the source
because annihilation photons are emitted approximately 180° apart (figure 2.1). In
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addition to trues events, there are also unwanted scattered and random coincidence
events. Scattered events occur when one or both of the annihilation photons undergo
Compton interactions before they reach the detector but still maintain enough energy to
be accepted in the PET energy window. The PET energy window is based around 511
keV, the energy of an annihilation photon. The exact width of the energy window is set
for each type of scanner to balance the scanners sensitivity to true annihilation events and
minimize the acceptance of scatter events. Random coincidence events occur when two
photons not associated with a distinct positronium annihilation events are detected within
the coincidence time window. Photons which cause random events may or may not be
from a positronium annihilation events. Background noise is limited in PET scanning
due to the use of thick lead or tungsten shielding around the detectors and the energy and
coincencedence time windows.

Figure 2.1 LOR (black line) and photon path (yellow line) based on true, scattered (blue
star), and random PET detection events (red star).
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The origin of the radionuclide decay along the LOR cannot be determined from the
detection of the annihilation photons alone. Therefore, prompt LORs are generally
plotted in a 2D histogram sorted by distance, r, from the center of the field of view (FOV)
and angle, , which will later need to be reconstructed to make an image. This plot is
generally known as a sinogram since a point source will create a sine wave plot (figure
2.2 a, b).

Figure 2.2 Simple circle and eclipse a) geometry used to provide examples of b)
sinogram, c) backprojection, and d) filtered backprojection
2.1.2

Corrections

PET is currently the most quantitatively accurate tomographic imaging method for
determining radionuclide concentraitons in tissue. However, before PET images can
provide quantifiable information, several corrections must be applied. First, a correction
is needed for random events. There are two common random correction methods, singlesbased and delayed random window correction (DRCC). In the singles-based correction
method, the randoms are estimated based on the single photon detection rates of the
detectors using the following relationship;
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Equation 2.1



  ,

where  is the coincidence time window and si and sj are the single photon detectrion rate
of detectors i and j respectively. The estimated randoms, Rij, can then be subtracted from
the prompts for each coincident circuit, ij, to provide an estimate of ture event rates(35).
However, the singles based correction method requires accurate estimates for the singles
rate for each detector, which can only be achieved with corrections for detector
limitations such as deadtime, pulse pile-up, localized efficiency, and energy resolution.
Inaccurate knowledge of these parameters can lead to bias in the randoms correction.
The second randoms correction method, DRCC, works by subtraction of delayed
coincidence events from the original prompt events. Delayed events are coincidence
events generated following a short termporal gap in one of the detector channels,
generally around 10 ns, which would make it impossible that both photons to have
originated from the same annihilation event. DRCC does not require corrections for the
detection problems specified above, but does does result in a lower signal-to-noise ratio
than the single event method due to the randoms coincidence detection event rate. To
reduce this noise, some DRCC corrections average, referred to as “smoothing” the
delayed events across adjacent coincidence LORs prior to subtraction. This requires the
delayed events to be transferred and processed prior to performing the correction while
the non-smoothed DRCC can be completed online as part of the data acquisition process.
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Scatter events also need to be corrected in order to produce unbiased quantitative
radionuclide concentration estimates.. Like randoms corrections, there are many types of
scatter correction methods. All datasets in this dissertation had a model based scatter
correction applied. Model based scatter correction consists of subtracting a predicted
scatter sinogram from the prompt sinogram following the random correction. The scatter
sinogram is created from a model using the attenuation map provided by the CT
associated with the PET and emission data to predict the events which were generated by
compton scatter. These models have been shown to accurately predict scatter inside the
field of view (FOV), but have difficulty predicting scatter events caused outside the
FOV(36). To remove the scatter from outside the FOV, the scatter sinogram is scaled to
fit the tails of the random corrected prompt sinogram. Since the tails of the sinogram
arise from outside the FOV, all tail activity is presumed to be from scatter events,
assuming the random correction was correct.
Corrections for attenuation is also needed since not all annihilation photons will reach the
detectors due to absorption and compton scattering. To correct for attenuation, most
modern clinical scanners have an associated CT which can provide attenuation correction
factors (ACF) created based on the attenuation of CT transmission. Since CT photons
have lower energy than annihilation photons, CT attenuation values are scaled to 511 keV
prior to the correction. ACF can then correct for attenuation through numerical itergration
for each LOR(37).
Normalization is additional correction which is made due to the differences in individual
crystal effeciencies from variations in PMT gains, detector block location and detector
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gaps. Normalization is completed through a periodic acquisition of an uniform source.
Since the source is uniform, all LORs would be expected to receive the same photon flux
and the normalization factor is calculated as,
Equation 2.2





,

where  is the mean coincidence counts across all LOR and Fi and Ai are the
normalization factor and coincidence counts for the ith LOR(38).
Deadtime is the final correction used during our PET acquisitions. Deadtime is the
period of time after a single event is detected that a new single can not be detected due to
detector or electronic recovery times. Deadtime corrections are extremely important
when there are high count rates, which has not the case with 90Y.
2.1.3

Reconstruction

Following corrections, the sinogram has to be reconstructed to create an image. There are
two general forms of PET image reconstruction algorithms, analytical or iterative.
Analytical algorithms are closed form solutions for the reconstruction. The most
commonly used analytical algorithm is filtered back projection (FBP), which is based
upon Radon transform theory. In FBP each measured LOR is projected back across the
image space to generate an image. However, if the projections were simplying back
projected, the low frequency would spread across the background of the image (Figure
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2.2c). Therefore, a filter is applied to introduce negative values into the projection,
suppressing the low frequency smear (Figure 2.2d).
Iterative algorithms are not closed-form solutions but rather numerical analysis solutions
for the reconstruction. Iterative algorithms can reduce the image noise as statistical
predictions can be included in the reconstruction. The most commonly used iterative
reconstruction is the expectation maximization (EM) method, which starts with an initial
estimation or guess of an image, which is then forward projected and compared to the
measured sinogram projections. The estimated projection is then backprojected to an
image where corrections are made for the differences found between the projections and
the process is then repeated. As the process is repeated, the reconstruction algorithm
converges to a final image. A limitation of iterative reconstruction methods is they are
computativelly intensive due to the number of iterations it takes to converge. To speed
up the process, ordered subset iterations were introduced. This approach works by
splitting up the entire sinogram into smaller subsets, which can then be iteratively
reconstructed at a faster speed.
As more iterations and subsets are completed, the image converges and becomes closer to
the final image. However, as the reconstruction becomes closer, image noise also
increases due to small changes in the data(39). To reduce this noise, reconstruction may
need to be stopped before complete convergence is reached or smoothing may need to be
applied after reconstruction. Since 90Y PET signal is very small, PET images will contain
a significant amount of noise. Therefore, the number of iterations and subsets used in
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reconstruction, in combination with a filter, are important parameters to consider in 90Y
PET acquisitions.
In many scanners today, including the Siemens Biograph 64 TruePoint PET/CT at
Indiana University Health University Hospital which was used in all our studies, data is
collected in a 3 dimensional acquisitions. Therefore, the 3D data needs to either be
rebinned or more complex algorithms need to be applied to reconstruct 3D sinograms.
All data in this work was rebinned prior to reconstrcution for both analytical and iterative
algorithms using Fourier rebinning (FORE) algorithm described by Defrise et al.(40).

2.2

Materials and Methods

To validate patient imaging results, images of a Jaszczak cylindrical phantom containing
cylindrical inserts with an inner diameter of 38 mm filled with 80 ml of known
concentrations of 90Y-Cl3 solution on a Siemens® Biograph TruePoint PET/CT. Total
activity was 1.01 ± 0.1 GBq, calculated by subtracting residual activity measured by a
Biodex Atomlab 100 dose calibrator from the supplier’s calibration record and corrected
for decay to the time of imaging. A 2.5 hour list mode acquisition was collected.
The acquisition was reconstructed using various reconstruction protocols. The current
clinically used algorithm is TrueX, a Siemens® commercial OSEM reconstruction with
point spread function recovery iterative reconstruction algorithm, at 2 iterations and 14
subsets (2i14s). The phantom was therefore reconstructed using TrueX® with various
iterations and subsets to evaluate their effect. Additionally, the phantom was analytically

23
reconstructed using DiFT. Commercial corrections for random, scatter, normalization,
deadtime, and attenuation were always applied.
All reconstruction protocols were evaluated in terms of accuracy and minimum
detectable concentration (MDC). Quantitative accuracy was determined by comparing
the observed syringe radionuclide quantity in the phantom images to the true activity.
Recovery coefficient (RC) was used as the figure of merit to determine quantitative
accuracy. Measured radionuclide quantities were calculated using a region growing tool
on CT images to create volumes of interest (VOIs). Each VOI was expanded 1 pixel
length (4mm) around its surface using MIMVista® software to ensure all activity in each
syringe was measured.
MDC is defined as the smallest activity within a standard volume which can be detected
at a specific confidence level, generally 95% and can be found using Curie’s equation:
Equation 2.3

   

 ,

where MDCnet is the minimum concentration that can be detected following background
subtraction and



b

is the measured standard deviation(41). The gross MDC was then

determined by adding the measured mean background concentration (Cb),
Equation 2.4
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To determine b, the 2.5 hr acquisition was divided into 10 minute frames to produce 15
different images for each reconstruction. Concentration from 10 background voxels
placed at random in the center of the phantom were then measured for each frame. The
measured mean and standard deviation across frames was determined for each voxel.
The image b was then defined as the mean of these 10 individual voxel standard
deviations and  was the mean of all voxel measurements.

Signal to noise ratio (SNR) was determined for the hottest insert in all reconstructions.
SNR was found by dividing the average by the standard deviation of the measured insert
concentration found across the frames. The SNR was then normalized to the clinically
used 2i14s TrueX reconstruction for comparison.

2.3

Results and Discussion

DiFT reconstruction was extremely noisy with an MDC of 3.1 MBq/ml (Figure 2.3).
Additionally, all insert measurements following DiFT reconstruction had RC less than
0.9 due to the presence of negative voxel values inside the VOI. DiFT SNR for the
highest concentration insert was only 73% that found in 2i14s TrueX reconstruction. Due
to extremely poor 90Y positron signal compared to background noise, DiFT
reconstruction inability to reduce noise, DiFT is not recommended for use in quantitative
90

Y PET/CT imaging due to its inability to include noise reduction into its reconstruction.
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Figure 2.3 Phantom image following DiFT reconstruction
As shown in Figures 2.4 and 2.5, increasing iterations and subsets in the TrueX
reconstruction showed an increase in the RC as the reconstruction converged (figure
2.5a). However, MDC was also found to increase with higher iterations and subsets
(figure 2.5b). The clinical 2i14s RC was found to be 90.8% for the hottest insert, with an
MDC of 1.07 MBq/ml. Increasing the clinical 2i14s one iteration only increases the RC
by 1.3%, while increasing the MDC 18.9%. Additionally, increasing the subsets to 21
only increased the RC by 0.6% while increasing the MDC 21.9%.
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Figure 2.4 Images created using various iterations and subsets in the TrueX
reconstruction
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Figure 2.5 Phantom analysis of for a) RC of the highest activity insert, b) phantom MDC,
and c) SNR normalized to 2i14s for various iteration and subset TrueX iterative
reconstructions. d) RC of all phantom inserts for various subsets using 2 iterations
The SNR was highest for 14 subsets. Additionally, the SNR increased 10% between 1
and 2 iterations, while increasing only 1.8% going from 2 to 3 iterations (Figure 2.5c).
Therefore, the recommendation is to continue using the current clinical 2i14s and is used
for the remainder of the study.
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Figure 2.5d demonstrates a positive bias at low concentrations. This positive bias leads
to an average measurable background concentration of 0.4 ± .1 MBq/ml following 2i14s
TrueX reconstruction. The positive bias is discussed further in chapter 4.
Table 2.1 PET insert 90Y activity measurements for scattered and non-scattered corrected
datasets following online and smoothed delayed random coincidence correction
Scattered
Non-scattered
Total activity
corrected
corrected
Insert
(MBq/ml)
Online Smooth Online Smooth
1
378.8
348.5
291.7
338.1
323.4
2
250.4
239.5
182.8
231.8
216.7
3
221.4
218.7
159.9
206.9
190.9
4
132.1
144.0
87.6
137.9
127.0
5
27.9
61.9
11.4
64.5
60.8

Smoothing the random sinogram prior to the random correction significantly changes the
results from the online random correction (table 2.1). The difference between the two
images is reduced if the scatter correction is turned off. Comparison of the scatter
sinograms shows the sinogram following the smoothed random correction is scaled
higher than following the online random correction (Figure 2.6). Since the smoothed
random correction leads to underestimation of all insert measurements, this indicates
smoothing the randoms prior to subtraction leads to an inadequate scatter correction. It is
likely that smoothing the randoms leads to an underestimation of randoms outside the
FOV, found in the prompt sinogram tail, since the scattered sinogram is scaled higher
than the online random sinogram. Further research is needed to determine the cause.
Due to the underestimation of results, the online random correction was used for the
remainder of the study.
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Figure 2.6 Total counts in scatter sinogram projections following online and smooth
DRCC

2.4

Conclusion

This study demonstrates that care should be taken when selecting reconstruction
protocols for quantitative 90Y PET/CT imaging due to its very low signal-to-noise ratio.
Closed form reconstruction solutions which are generally desired for quantitative
analysis, such as DiFT, are not recommended for 90Y imaging due to its inability to
incorporate noise reduction into the reconstruction. Smoothing the random sinogram
before the random correction is not recommended due to reduced activity recovery
believed to be caused by inadequate random correction in the sinogram tails, leading to
erroneously high scatter correction. For the Siemens® Biograph 64 PET/CT TruePoint
scanner, the recommended reconstruction protocol was found to be 2i14s TrueX with
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online random correction based on a balance between MDC limitations, quantitative
accuracy, and SNR.
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CHAPTER 3. ORIGIN OF 90Y PET SIGNAL AND NOISE

3.1

Introduction

Substantial research has demonstrated the feasibility of producing PET images following
radioembolization. However, few studies have been performed exploring coincidence
count rates associated with 90Y PET imaging. Due to the very small internal pair
production decay branching ratio of 90Y, the PET signal from positron annihalition events
will be extremely small even while imaging the large doses used in radioembolization
therapy. A typical therapeutic dosage of 2.4 GBq of

90

Y only produces 76481 positrons

per second, equivelent to the positron production rate of 79 kBq of 18F which is the most
common PET radioisotope due to its 97% positron emission rate. This is significantly
smaller than the hundreds of MBq used for clinical diagnostic PET imaging procedures.
As discussed in chapter 2, random coincidence counts are a source of noise which need to
be corrected for when reconstructing PET images. In clinical PET imaging where the
positron annihilation or “true” signal is much higher, random coincidences generally arise
from the detection of two photons from different annihilation events. The signal from
these radiopharmeceuticals is enough to dominate the singles rate, making random
coincidence counts increase roughly proportionally with the square of source activity as
demonstrated in equation 2.1. However, the annihilation photon rate from 90Y will be
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much lower than for standard PET radionuclides. Therefore, photon sources other than
annihilation photons dominate the observed single event rate leading to randon to true
event ratios that are very different than observed with standard PET radionuclides. This
study will evaluate single and coincidents event rates observed when imaging 90Y.
from sources other than annihilation events will likely have a greater impact on the
singles rate and therefore effect random events differently. This study will evaluate the
origin of singles and coincidents events to evaluate the PET signal associated with 90Y
imaging.
The first non-annihilation photon source which may lead to random coincidence counts is
present only in PET systems which use Lutetium (Lu) based scintillators, such as Lu
Oxyorthosilicate (LSO) or Lu-Yttrium oxyorthosilicate LYSO crystals. Lu used in these
crystals contain radioactive iosotope 176Lu at its natural abundancy of 2.6%. 176Lu decays
through - decay, with a mean energy of 420 keV, followed by prompt emission of
gamma ( ) rays with energy of 307 keV (94%), 202 keV (78%), and 88 keV (15%)(42)
(figure 3.1).
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Figure 3.1 Natural Lu-176 decay schematic
Some of the 176Lu - particles will contain energies which fall within the energy window
and will produce single events, and therefore increase random coincidence events.
Additionally, if two of the photons in the cascade following the - emission both hit the
same detector block, they can build up to create a pulse which can fall into the PET
energy window requirements and create a measured event. With this hit, prompt
coincidence event can be made with the hit from the detection of the - particle. It has
been shown in the past that both the random and prompt coincidences from 176Lu produce
count rates significantly lower than the count rates from clinically used activities of
positron emitting radiopharmaceuticals as long as the PET lower energy threshold is set
greater than 350 keV(43, 44). As clinical scanners generally have lower energy

34
thresholds greater than 350 keV, coincidence counts from 176Lu are generally ignored.
However, since 90Y signal is so low, it is expected 176Lu will lead to substantial
proportion of the count rate and are explored in this study.
Another source of non-annihilation photons is Bremsstrahlung produced by high energy

 particles emitted in 90Y decay as they travel through tissue. With a maxiumum 
energy of 2.28 MeV, these bremsstrahlung photons can have energies which meet PET
energy window requirements, leading to increased single event rates and therefore
random counts(45).
Additionally, the bremsstrahlung photons can have energies greater than 1.022 MeV
which can result in pair production as the photon interacts with matter. Bremsstrahlung
pair production rates are expected to be a very small proportion of coincidence counts as
only a small fraction of bremsstrahlung photons will have enough energy to create a pair
production event. This event would then need to occur in a specific geometry to
complete a coincidence circuit and create a PET coincidence count. This geometry is
unique as the probablity of photons with energy below 2 MeV interacting with a low Z
material, such as tissue, is extremely low. Therefore, the only photon pair production
which could be registered would be when the pair production occurred in the detectors
scintilation crystals themselves. This would lead to an unique detection scenerio as the
positron which is produced through the pair production would deposit its energy inside
the crystal. Therefore, the true event would be counted only if the positron had energy
within the PET energy window and one of the annihilation photons was detected in
another block to complete the coincidence circuit. Therefore, true events produced by
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bremsstrahlung pair production are expected to be extremely rare but for completeness,
are still evaluated in this study.
The purpose of this chapter is to explore the signal and noise associated with 90Y PET
imaging using both experimental data and Monte Carlo (MC) simulations. This study
will evaluate the relationship between random coincidence event rates , 90Y activity
levels, the proportion of counts which arise from 176Lu present in the detector crystals,
and bremsstrahulung photons associated with the 90Y - decay.

3.2
3.2.1

Materials and Methods

GATE model Monte Carlo Simulation

MC simulations are routinely used to computationally model radioactive particle
interactions with matter in physics problems. MC uses random number generators to
model particles interactions with matter based on the statistical probabilities of
interactions. There are numerious software packages available which provide particle
transport MC simulations. A popular MC software specificatly designed for medical
applications known as Geant4 Application for Tomographic Emission (GATE)(46), is
used in this study. GATE is popular for nuclear medicine applications as its user friendly
macros are specifically designed for modeling imaging modalities, while being
incorporated with a much larger and complex MC software package known as
GEneration ANd Tracking (Geant4)(47).
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The GATE model created in this study was for our scanner, the Siemens Biograph 64
TruePoint PET/CT to predict the origin of all coincidence counts produced with 90Y
decay. This model was comprised of 4 rings in accordance with the Biograph TruePoint
geometry (Fig 3.2). Each ring contained 48 detector blocks, which contain 169 Lutetium
Oxyorthosilicate (LSO) crystals in 13 x 13 arrays. The individual crystals have a surface
areas of 4x4 mm2 and depth of 20 mm. The system geometry was implemented based on
private communications with Siemens. A carbon fiber bed, PMT, and lead end shields
were also included in order to appropriately model photon attenuation and scatter.

Figure 3.2 Gate model displaying crystals, blocks, PMT, gantry table and phantom
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GATE uses Geant4 physics models to simulate electromagnetic transfer processes, with
standard and low energy Penelope models being most common for tomography
simulations. In this study, the low energy Penelope model was used for Rayleigh
scattering. Photoelectric, electron ionization, Bremsstrahlung, gamma conversion, and
compton scattering physics processes were modelled using standard models to minimize
computational time. Table 3.1 provides the threshold “cuts” which were used for
secondary particle and radiation production to optimize computational runtime.
Table 3.1 Particle cuts for GATE simulation model
Particle
Phantom
Crystal
Gamma

10 keV

50 keV

Electron

0.1 mm

1 cm

Positron

0.1 mm

1 cm

In addition to geometry, GATE also models the behavior of detector response and signal
processing through a digitizer module. This module starts once a detector is hit, which is
defined as a physical interaction with the models sensitive detector, or crystals in our
module. The GATE digitizer module then processes these hits to determine the
coincidence counts which would be registered by the scanner using a number of digitizer
macro commands. The digitizer module parameters used in our model of the Siemens®
Biograph TruePoint 64 are shown in Table 3.2.
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Table 3.2 Digitizer module parameters used in the Siemens Biograph TruiPoint 64
PET/CT GATE model
Module Name
Description
User Defined Paramenters
Adder

Sums all energy in a single
crystal into one pulse.

NA

Readout

Combines all pulses from a
sensitive volume into one
output pulse.

Sensitive Volume = Block

Time Resolution

Adds time resolution of the
crystal

Time Resolution = 500 ps

Crystal Blurring

Adds efficiency and blurs
energy based on crystal
properties

Energy Resolution = 15% at 511
keV
Crystal Efficiency = 0.9

Deadtime

Adds crystal deadtime

Time = 136 ns
Module = paralysable

Energy Threshold

Changes pulses into singles
based on PET energy
threshold

Lower Thresholder = 435 keV
Upholder = 650 keV

Coincidence Sorter

Sorts singles into coincidence
pairs

Coincidence window = 4.5 ns
Coincidence offset = 0 ns

3.2.2

Phantom Validation

A 10 minute duration scan of the PET phantom described in chapter 2 was acquired once
a day for 5 consecutive days to produce image data sets with varying 90Y activites.
Phantom studies were performed with the MC simulation model in order to validate the
models ability to predict prompt and random coincidence count rates.

90

Y Geant4

radionuclide sources set to the concentrations inside the cylidrical inserts were used to
model the - decay. As the 90Y internal positron emission is not included in the Geant4
ion source model, 511 keV back-to-back gamma photons were also included at the
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3.1867e-5 branching ratio. To mimic the natural radioactivity present in the crystals, a
176

Lu radionuclide source was created confined to the crystal volume was inlcuded in the

model. The total activity of 176Lu was determined by matching the randoms coincidence
rate to the cold acquisition.

3.2.3

Evaluation

Average relative percent error was calculated using the following equation to establish
the correspondance between the GATE model and data measured with the Biograph-64,
Equation 3.1

 

 ,


Where Cs and CA where coincidence count rates from the simulation and phantom
acquisition, respectivily. The prompt to random noise ratio (PRR) was calculated by;
Equation 3.2







where P are prompt coincidence counts and R are random coincidence counts.
Additionally, the prompt coincidence counts were compared from individiual phantom
cylindrical inserts by comparing the fractional count rates arising from each insert to the
fraction of the total activity found in each insert. The standard deviation, as shown in
figure 3.3, for the fractional activity was determined by variance propogation assuming
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10% error in each insert activity as described in chapter 2. All 5 simulations were used to
determine the simulation sample standard deviation using the standard equation,
Equation 3.3




   



3.3

Results

The total background coincidence rate from natural 176Lu was observed to be 1027.3
coincidences per second (cps) in the cold acquisition. The majority of these coincidences
came from random counts, 1020.3 cps, while 7.0 cps were registered as true/scatter
coincidence counts. A total 176Lu activity of 1.975 MBq confined to the crystal volume
was used to match this coincidence rate. The simulated coincidence cout rates for
true/scatter and random coincidences was 1018 and 4.5 cps, respectively.
The simulation was able to predict prompt and random coincidence rates for all five
phantom acquisitions (Table 3.3). The average relative percent error between the
simulation and experiemental prompt and random coincidence rates was 3.3±1.7% and
2.1±1.4%, respectively.
The random events were found to increase with increasing 90Y activity. However, this
increase was found to be approximately proportional to 90Y activity, not the square of
90

Y activity (Fig. 3.2). The majority of this increase was found to be produced by one

176

Lu and one bremsstrahlung photon being detected in coincidence (Fig 3.2). In the
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highest activity phantom, only 1% of random events were produced without one photon
from 176Lu. A random event rate of only 0.5 cps could be attributed to two separate
annhilation events from 90Y pair production.
Table 3.3 Phantom prompt and random coincidence count rates and signal to noise ratios
for the GATE simulation (sim) and experimental (exp) phantom acquisition
90
Y
Exp.
Sim.
Exp. R Sim. R
Exp.
Sim.
Day
Activity
P
P
(CPS)
(CPS)
PRR
PRR
(MBq)
(CPS) (CPS)
1
1008
1412 1454
1201
1218
0.19
0.18
2
793
1312 1365
1161
1176
0.16
0.13
3
610
1220 1290
1106
1156
0.12
0.10
4
475
1182 1216
1089
1112
0.09
0.08
5
362
1161 1173
1091
1105
0.06
0.06

1250
R² = 0.9672
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Figure 3.3 Increase of random coincidence counts are proportionally linearly to 90Y
activity

42

Random coincidence count rate (CPS)
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Figure 3.4 Random coincidence counts originating from LSO, bremsstrahlung (brem),
and pair production annhiliation (pp) photons single detection hits found using GATE
simulation of the highest activity 90Y phantom PET acquisition
Detection of the LSO  decay and cascade photons was found to produce only 3
additional prompt coincidence counts per second. Additionally, detection of the
annihilation photons from high energy bremsstrahlung photons pair production was found
to only produce 1 prompt coincidence counts per second. Combined, this produced less
than 2% of all true coincidence counts, in the phantom with the highest activity.
Figure 3.4 demonstrates that the fraction of true counts from each insert matches within
one standard deviation the fraction of activity in each insert. This is even true in the
lowest activity insert, whose concentration was always below the MDC of 1 MBq/ml as
described in chapter 2.
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Figure 3.5 Fractional coincidence counts from inserts compared to proportional activity
for phantom acquisitions
3.4

Discussion

The results of this study demonstrate that GATE can accurately simulate the prompt and
random count rates of 90Y acquisitions on a Siemen’s Biograph TruePoint 64 PET/CT.
To the best of my knowledge, this is the first simulation which models 90Y PET signal as
well as this particular scanner. This simulation illustrates the extremely low prompt
signal to random noise associated with

90

Y imaging on LSO PET scanners, showing that

even at 1 GBq the PRR is below 0.2.
In addition to detection of 90Y annihilation photons, GATE predicted only 3 cps of
additional true coincidence counts in the phantom containing 1 GBq. As expected, only a
very small proportion of true coincidence counts were the result of high energy
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bremsstrahlung pair production, with producing only 1 prompt cps, or 0.6% of all prompt
counts, in the highest activity phantom acquisition.
The other non-90Y true event occured from the cascade decay of 176Lu. Again, this is an
unlikely occurance since the 176Lu - energy would have to create one single, and the pile
up of two of the cascade gamma’s would have to create the other due to energy window
requirements. This appeared to occur at a rate of approximately 2 coincidences per
second regardless of the activity inside the phantom. This equates to about 1% of all
prompt coincidences observed with 1 GBq of

90

Y.

The LORs created by the LSO and bremsstrahlung pair production would not necessary
line up with the source location since these true events did not originate from the 90Y
source. Therefore, these events would produce background noise that would be
distributed throughout the image. However, since these events only contribute to a very
small fraction of true events and therefore would not generate significant background
noise.
In addition to the true events, the origin of the random events was also analyzed in this
study. Due to the extremely low positron signal of 90Y, the majority of the random counts
are due to the intrensic 176Lu in the LSO crystals. The model showed there was no
increase in randoms counts observed from detection of two photons from different
annihilation events as is generally the case with diagnostic PET radiopharmeceuticals.
However, randoms increase with 90Y activity, mostly due to the presence of
bremsstrahlung photons. The majority of this increase was due to the detection of one
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bremsstrahlung photon and one 176Lu. Therefore, detectors without Lu based crystals
would be expected to have better counting statistics for 90Y imaging.
Finally, the fractional count rates from the phantom inserts in the simulation were found
to line up with the fraction activity from the phantom acqusition. This demonstrates that
the MDC of 1 MBq found in chapter 2 and described again in chapter 4 for this
reconstruction is not due to the detection of the positron signal but is due to the large
noise presense. Therefore, an accurate correction for random events is essential for 90Y
imaging.

3.5

Conclusion

The study demonstrated the feasibility of using a MC simulation created in GATE can
accurately simulate the count rates associated with 90Y acquisitions on a Siemen’s
Biograph TruePoint 64 PET/CT. Using this simulation, these count rates can be
evaluated to demonstrate the extremely poor prompt signal to random noise associated
with 90Y due to the large presence of random coincidence counts associated with
bremsstrhalung and 176Lu photons. Therefore, the accurate corrections for random events
areshown to be essential for 90Y imaging.
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CHAPTER 4. THE IMPACT OF 90Y PET IMAGE RECONSTRUCTION BIAS ON
PATIENT DOSIMETRY FOLLOWING RADIOEMBOLIZATION

4.1

Introduction

As shown in the previous chapters, 90Y is not an ideal PET radionuclide due to its low
SNR, producing an image acquisition scenario with high random to true coincidence rate
ratios. In this type of scenario, the DRCC which corrects for random coincidence counts
can lead to negative sinogram values as a result of the stochastic nature of radionuclide
decay. These negative values are often truncated in commercial software packages prior
to reconstruction to provide concavity in iterative reconstruction algorithms. This
sinogram element truncation is known to cause positive bias(48-50). The purpose of the
study described in this chapter was to evaluate the magnitude of this bias in 90Y PET/CT
images reconstructed following this truncation and to assess the feasibility of utilizing
90

Y PET/CT images to estimate 90Y dosimetry in tumor and treated lobe parenchymal

volumes following radioembolization.
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4.2
4.2.1
90

Materials and Methods

Image Acquisition and Reconstruction

Y PET/CT patient studies acquired approximately 1 hour after right or left hepatic

artery TheraSphere® injection at Indiana University hospital in Indianapolis, IN between
February 2011 to January 2013 were analyzed retrospectively. The Indiana University
institutional review board approved this retrospective study and the requirement to obtain
informed consent was waived.
Data acquisition durations were 10 minutes per bed position on the Siemens PET/CT
Biograph® 64 TrueD and had vendor supplied DRCC, decay, scatter, normalization, and
attenuation corrections applied. Patient images were acquired using Siemens' net
acquisition mode, which corrects for randoms real time and reconstructed using Siemens’
iterative reconstruction algorithm with point spread function spatial recovery, TrueX®,
which truncates negative ray-sum values in the sinogram prior to image
reconstruction(13). Images were reconstructed with 2 iterations, 14 subsets which results
from chapter 2 demonstrated provided the best compromise between accuracy and noise.
PET DICOM image arrays were post processed in IDL (Interactive Data Language,
Research Systems Inc., Boulder, CO, USA) to apply the 90Y positron branching ratio and
proper decay correction for quantification.
The cylindrical phantom acquisitions collected over 5 days described in chapters 2 and 3
were used to validate patient image results. In addition to the net acquisition mode,
phantom data were also collected using a prompt/random acquisition mode. The
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prompt/random acquisition mode saves both prompt and delayed sinograms, enabling
averaging or smoothing of the delayed sinogram bin values prior to DRCC. Given the
delayed sinogram provides an estimate of random coincidence rates, smoothing the
sinogram reduces variance introduced during the DRCC(35, 51). In addition to TrueX®
reconstruction, phantom data was also reconstructed using DiFT with and without
sinogram truncation to evaluate the effect of sinogram truncation. Quantitative accuracy
and MDC were found as described above in section 2.2.

4.2.2

Image Bias

Image bias was determined by comparing the administered quantity of 90Y to the
measured radionuclide quantity across the image field of view (FOV). For the patient
studies the administered 90Y quantity was defined as injected activity, minus the
estimated lung shunt fraction (LSF) for image volumes that excluded the majority of the
lungs. Manufacturer calibration records were used to determine the injected 90Y activity
for each patient, corrected for decay and residual activity. A 10% uncertainty was
assumed for the assay of 90Y quantities. The LSF was determined by a pre-treatment
SPECT scan of 99mTc-MAA injected during the patients planning arteriogram performed
approximately 2 weeks before radioembolization. PET images with 2 bed positions
contained a majority of the lung in the FOV, and therefore no subtraction was made to
remove the lung activity in defining the administered FOV quantity. The administered
whole liver quantity was corrected for the LSF in all studies.
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For the phantom studies, the total radionuclide quantity measured across the entire PET
FOV was compared to the total syringe activity. Using IDL software, net acquisition
uncorrected sinogram values were binned to create a histogram to demonstrate the
distribution of positive and negative values observed following real time DRCC.
Prompt, random, and true events were recorded from multiple acquisitions of 90Y and
fluorine-18 (18F) point sources to evaluate the impact of bremsstrahlung photons on
random coincidence count rates. Three acquisitions of 90Y activities of 3.8, 1.7, and 0.2
GBq, contained in original TheraSphere® vials, were collected. Additionally, 4
acquisitions were collected every half hour with a vial filled with 18F. The 18F activity for
the first acquisition was 0.13 MBq, decay corrected from an initial activity of 8.5 MBq as
determined by the dose calibrator. An additional acquisition was collected with no
activity present to determine the background count rate.

4.2.3

Absorbed Dose Maps

PET radionuclide concentration images were converted to dose maps in accordance with
MIRD 17(52). Voxel S values were constructed for the PET voxel size (4.07 x 4.07 x 3
mm) using Monte Carlo radiation transport code MCNPx,(53) using 108 starting particles and a cutoff energy of 1 keV. Dose maps were generated by convolving the
voxel S values with PET DICOM cumulative activity arrays in IDL.
Phantom syringe VOI dose measurements were used to validate dose map results through
comparison with expected dose values using the clinical dosimetry equation:
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Equation 4.1






where A is activity in GBq, M is mass in Kg assuming liver tissue density, and D is dose
in Gy(5).

4.2.4

Patient Dosimetry

Figure 4.1 illustrates radiologist defined contours of the lesion (blue) and treated lobe
(green) created on the PET associated CT images used to determine radionuclide
quantities and tissue volumes for all patient studies. Necrotic volumes (red) were also
contoured to separate from viable lesion volumes.
Only tumors greater than 1 cm were included in the study. Studies with indiscernible
tumor boundaries were excluded. In studies with large necrotic centers, the tumors were
contoured to differentiate between viable and non-viable tumor volumes. Healthy normal
tissue parenchymal contours were constructed by removing tumor volumes from the
treated lobe contours. Mean tumor doses were estimated by placing the contours on the
PET dose maps.
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Figure 4.1 Patient PET/CT images following a) 3.6 and b) 3.2 GBq uni-lobar 90Y
radioembolization demonstrating radionuclide quantity observed throughout the field of
view
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Figure 4.1 illustrates radiologist defined contours of the lesion (blue) and treated lobe
(green) created on the PET associated CT images used to determine radionuclide
quantities and tissue volumes for all patient studies. Necrotic volumes (red) were also
contoured to separate from viable lesion volumes.
Only tumors greater than 1 cm were included in the study. Studies with indiscernible
tumor boundaries were excluded. In studies with large necrotic centers, the tumors were
contoured to differentiate between viable and non-viable tumor volumes. Healthy normal
tissue parenchymal contours were constructed by removing tumor volumes from the
treated lobe contours. Mean tumor doses were estimated by placing the contours on the
PET dose maps.
Measured quantities are expected to be overestimated in voxels with concentration below
the MDC. The maximum potential activity from bias can be quantified assuming all
activity in voxels below the MDC is from bias. MIMVista® upper bound threshold tool
set to the MDC was used to determine this maximum bias activity for each VOI.
Maximum bias activity can be converted to maximum dose bias by separating the activity
from measurements above and below the MDC in the clinical dosimetry equation,
Equation 4.2
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In this equation,  represents the activity measured above the MDC,  is activity
measured below the MDC, and M is the whole volume mass. The second term, with the
activity measured below the MDC, represents the potential dose bias.

4.2.5

Statistical Analysis

Data is expressed as mean ± standard deviation. Phantom VOIs with concentration above
and below the MDC quantitative accuracy measurements are compared with the
nonparametric Wilcoxon rank sum test since the continuous measurements were not
normally distributed.

4.3
4.3.1

Results

Image Reconstruction Bias in Patient Acquisitions

Sixty-five (65) PET/CT acquisitions following right (n=48) and left (n=17) hepatic artery
radioembolization from 59 patients were included in the analysis, with 16 and 49 having
1 and 2 bed positions, respectively. The mean injected activity was 2.6 GBq, with a range
of 0.7 to 5.7 GBq. The mean LSF was 5.3 ± 2.6% and 7.6 ± 4.0% for 1 and 2 bed
positions, respectively. Diffuse background activity was observed in all patient PET
images (Figure 4.1). Total image FOV measured radionuclide quantities exceeded the
administered radionuclide quantity by an average of 8.4 and 13.5 GBq for 1 and 2 bed
positions, respectively when using TrueX® following net acquisition (Figure 4.2). The
mean measured quantity in whole liver VOIs was 0.6 ± 0.6 GBq greater than expected.
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Figure 4.2 Excess FOV activity observed in patient PET/CT images following net
acquisitions reconstructed using TrueX®
4.3.2

Phantom Image Reconstruction Bias

Bremsstrahlung photons increased the 90Y random coincidence event rates compared to
18

F for equivalent positron emission rates, while true plus scatter count rates were found

to be similar (Figure 4.3). At 3.8 GBq, 90Y provided a 3.06 fold increase in random
events compared to background coincidence rates observed with no activity present.
However, interpolation of the 18F random event rate results showed 18F at the same
positron emission rate of 121.5 k-positrons (0.13 MBq of 18F) only produced random
events at 1.03 times background.
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Figure 4.3 Coincidence count rates for 18F and 90Y point source PET acquisitions
A histogram of detected highest activity phantom ray-sum values, following net
acquisition, demonstrated 46.8% of non-zero values were negative (Figure 4.4). Phantom
net acquisition images with real time DRCC subtraction had radionuclide quantities
measured across the FOV that exceeded the total radionuclide quantity placed in the
syringes, with percent errors in the range of 273 to 747% observed during the first five
days of imaging (Table 4.1, Figure 4.5A). The range dropped to -0.6 to 26% when the
delayed window was smoothed with the prompt/random acquisition, with the highest 3
activity images having less than 10% error (Figure 4.5B).
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Figure 4.4 Histogram of sinogram ray-bin values following phantom acquisition of online
DRCC subtraction
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Figure 4.5 Reconstructed images from a) net and b) prompt/random acquisitions of the
phantom illustrating decrease of background diffuse bias following random smoothing
prior to DRCC in the prompt/random acquisition model
Additionally, positive bias was not observed in any images following net acquisition
using DiFT reconstruction. Positive bias was observed following DiFT reconstruction
when the net acquisition sinogram was truncated prior to reconstruction.
Table 4.1 Total phantom FOV calculated activity following various reconstructions and
acquisitions

Day

True
Activit
y
(MBq)

TrueX,
Net Acquisition
(MBq)
[Percent Error (%)]

TrueX,
Prompt/Random
Acquisition (MBq)
[Percent Error (%)]

DiFT, Net
Acquisition (MBq)
[Percent Error (%)]

1
2
3
4
5
13

1008
793
610
475
362
34.7

3755 [273]
3562 [349]
3282 [438]
3140 [561]
3067 [747]
2596 [7381]

1002[-0.6]
819 [3.3]
628 [3.0]
529 [11]
454 [25]
147 [324]

800 [-21]
616 [-22]
446 [-27]
318 [-33]
244 [-33]
-46 [-233]

Truncated DiFT,
Net Acquisition
(MBq)
[Percent Error (%)]
3250 [222]
3135 [295]
2935 [381]
2777 [485]
2752 [660]
2362 [6707]
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4.3.3

Quantitative Accuracy

The 90Y MDC for the net acquisition using the TrueX reconstruction was found to be 1
MBq/ml. Quantity and dose measurements from the 16 syringes containing activity
above the MDC matched expected values within 10% (Figure 4.6, Table 4.2). VOI
measurements in the 9 syringes with concentrations below the MDC were higher than
expected. The positive bias observed in the syringe VOIs with concentrations below
the MDC produced absolute errors that were greater than the absolute errors observed for
VOI measurements in syringes with concentrations above the MDC (p<0.0003).
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Figure 4.6 Phantom insert VOI measurement a) accuracy and b) percent error for images
reconstructed using TrueX® following net acquisition
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Table 4.2 Phantom image activity and dose estimated from TrueX® reconstruction of
data collected using the net acquisition mode
Dose
Syringe
True
VOI
Expected Calculated
Day/
Percent
Concentration
Activity
Activity
Dose
Dose
Syringe
Error
(MBq/ml)
(MBq)
(MBq)
(Gy)
(Gy)
(%)
1/1
378
347
147
135
-8.4
4.72
2/1
297
268
113
102
-9.9
3.71
1/2
250
230
99
91
-8.1
3.12
3/1
229
217
88
86
-2.3
2.86
1/3
221
208
85
80
-3.2
2.76
2/2
196
185
74
70
-6.1
2.45
4/1
178
181
72
71
-0.8
2.22
2/3
174
164
66
62
-6.0
2.17
3/2
151
150
59
60
1.9
1.89
5/1
136
137
57
57
1.0
1.69
3/3
134
138
51
54
6.5
1.67
1/4
132
144
51
56
9.4
1.65
4/2
118
112
49
49
0.9
1.47
4/3
104
112
41
43
4.0
1.30
2/4
104
107
39
41
3.2
1.30
5/2
90
97
38
41
8.3
1.12
3/4
80
96
31
39
24.8
0.99
5/3
79
92
32
37
16.5
0.99
4/4
62
86
24
34
38.7
0.78
5/4
47
69
19
28
45.8
0.59
1/5
28
59
11
24
113.1
0.35
2/5
22
52
9.1
22
138.5
0.27
3/5
17
49
6.6
20
206.9
0.21
4/5
13
45
5.4
19
244.4
0.16
5/5
10
41
4.2
17
317.9
0.12

4.3.4

Patient Results

From the 65 studies, the treated lobe concentration based on expected liver activity
assuming uniform distribution was greater than the MDC (range 1.03 – 3.64 MBq/ml).
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However, visual observation confirmed 90Y was heterogeneously distributed, resulting in
an average treated lobe volume below the MDC of 277.4 ± 204.1 ml, with a range of 25.9
to 1353.7 ml. Due to increased uptake in the tumor, the majority of this volume was
found in the parenchyma with an average of 247.8 ± 149.0 ml, corresponding to an
average of 27.3 ± 16.9% of the total parenchyma (Figure 4.7A). The mean total quantity
measured in the treated parenchyma volume with 90Y concentrations below the MDC was
170.1 ± 99.4 MBq. This resulted in a mean potential bias of 8.9 ± 4.9 Gy, with 42%
(27/65) of the studies having potential dose bias larger than 10% the uniform
parenchymal dose (Figure 4.7B).
The volume below the MDC in the 115 identified tumors was 16.7 ± 75.8 ml,
corresponding to 12.2 ± 23.1% of lesion volume, resulting in an average total measured
quantity of 15.8 ± 55.3 MBq. This resulted in a mean potential bias of 3.3 ± 6.4 Gy, with
only 9% (10/115) of the studies having potential dose bias larger than 10% the uniform
lesion dose, all of which had poor (Figure 4.7C). The 10 studies with greater than 10%
bias all showed poor preferential 90Y deposition with calculated uniform dose of less than
100 Gy.
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Figure 4.7 Parenchyma and lesion contours a) fractional treated lobe volume with
measured concentration below the MDC and the associated potential overestimation in
dose due to potential bias from measured activity in these volumes for the b) parenchyma
and c) lesions
4.4

Discussion

A large positive bias in the total radionuclide quantity in patient 90Y PET/CT images was
observed when negative sinogram values were truncated prior to iterative reconstruction.
Based on the phantom study, the positive bias was found to be restricted to regions where
90

Y concentrations fall below the MDC. The study demonstrated that 90Y PET/CT

measured radionuclide concentration is quantitatively accurate, even in the presence of
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significant positive bias within the image volume, in areas found to contain 90Y
concentrations above the MDC.
In the setting of very low coincidence detection rates and high single event rates (as
observed in our 90Y PET studies) a large number of the sinogram elements are negative
following online DRCC due to the stochastic nature of the random coincidence events
detected in both the prompt and delayed coincidence windows. Truncation of negative
values leaves only the positive values of the background noise distribution in the
sinogram. Reconstruction of sinograms in which negative values have been truncated
artificially generates radionuclide concentrations in regions of the image that have very
low radionuclide concentrations while having minimal impact on the reconstructed value
in regions of the image with high radionuclide concentrations. Our phantom studies with
and without sinogram truncation when using the DIFT reconstruction algorithm provide a
nice demonstration of the impact of truncation in the setting of low coincidence rate and
high single event rate PET studies. Our study also demonstrated that smoothing the
delay window random coincidence rates prior to subtraction reduced the observed bias.
This type of positive bias is well-documented for PET images reconstructed using
iterative algorithms with truncated sinograms in the setting of low signal to noise
ratios(33, 34, 36).
Past studies have suggested that at low signal, natural radioactive decay of 176Lu, found in
LSO PET crystals, can cause the majority of the random events leading to the positive
bias(54). However, the experimental findings from the 90Y point source study showed an
increase in random coincidences for the 90Y source as compared to background or
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equivalent rate of positron emission from an 18F source. As shown in chapter 3, this
increase is due to bremsstrahlung photons produced by the 90Y 2.28 MeV maximum
energy -particle. Truncation of negative sinogram values produced by the correction for
these random events creates a mean excess of 8.4 GBq across the FOV for a 1 bed
position study. In comparison, the 1-bed position study of the cold phantom produced an
excess of 2.6 GBq. Therefore, the biased background signal observed in regions below
the MDC is due to both bremsstrahlung and natural radioactivity in LSO crystals.
Even with the large positive bias observed when quantifying the radionuclide levels
throughout the imaging FOV, the phantom study demonstrated quantitative accuracy for
concentrations above the MDC, confirming previous literature findings that 90Y PET
images are accurate at high concentrations(28, 54). Through use of voxel MIRD
methodology, these images also provided accurate dose results for each of these VOIs.
As expected, bias was observed in VOIs with concentrations less than the MDC, resulting
in an overestimation of both radionuclide concentration and radiation dose.
Overestimation of the quantity of 90Y in the liver volume was evident in all 65 patient
studies, even when considering a 10% uncertainty in the original 90Y assay. Positive bias
is expected to have influenced dose results for all patients in this study due to areas with
concentration below the MDC of 1 MBq. However, due to preferential uptake of 90Y
microspheres in tumors, the majority of tumors had a very small volume with
concentrations below the MDC. This favorably results in minimal positive bias within the
tumor volume. Thus the potential for error in 90Y concentration estimates from the bias
in most tumors was found to be relatively small. Ninety one percent (105/115) of
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identified tumors had a potential bias of less than 10 Gy. The 10 tumors which had a
potential bias greater than 10 Gy were found to all have calculated doses less than 100 Gy
due to low 90Y deposition. In these 10 tumors, the calculated dose is still known to be less
than 100 Gy since the bias is positive.
Unfortunately, the non-uniform distribution resulted in large portion of the parenchymal
volume to be below the MDC. This resulted in an average potential bias of 8.9 Gy, with
40% (26/65) of studies having a potential bias greater than 10 Gy due to the image
reconstruction bias. This observation demonstrates that great care must be taken when
trying to assess radiation dose to normal liver parenchyma based upon 90Y PET images
when using reconstruction algorithms that employ truncation of negative sinogram
values.

4.5

Conclusions

Due to low positron signal compared to noise from LSO and bremsstrahlung photons, a
large number of sinogram ray-sum values are negative following DRCC subtraction,
leading to position bias when truncated in iterative reconstruction algorithms. Even in
the presence of this positive bias, quantitative accuracy was good in areas where the
concentration is above the MDC, enabling accurate estimation of 90Y PET/CT tumor
dosimetry following radioembolization. A large positive bias was observed in regions
with low 90Y concentrations, such as found in large areas of the parenchyma in many
studies, when using sinogram truncation with iterative reconstruction. Therefore, care
must be taken in the selection of reconstruction algorithm for estimation of radionuclide
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concentration and dosimetry in low uptake regions of the image such as the liver
parenchyma.
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CHAPTER 5. VERIFICATION OF 90Y PET DOSIMETRY USING POLYMER GEL
DOSIMETRY

5.1
5.1.1
90

Introduction
Background

Y microsphere distribution is not uniform across the treated liver lobe following

radioembolization. Consequently, the treatment dose distribution is not uniform.
Previous studies designed to validate voxel-based dose maps generated using PET or
SPECT imaging methods used uniform phantoms with homogeneous distributions of 90Y.
To the best of our knowledge, no evaluation has been conducted verifying 90Y dose maps
using a heterogeneous validation method.
In external beam radiotherapy polymer gels(55-57) have been used to verify
heterogeneous dose distributions. In addition, polymer gels have been proposed as a
method for quality control of dosimetry following SPECT imaging of Iodine-131 targeted
radionuclide therapies(58). In this study, we propose using polymer gel dosimetry to
independently verify heterogeneous dose maps produced using 90Y PET/CT images.

5.1.2

Polymer Gel Dosimetry

Polymer gels designed as dosimeters are manufactured using radiation sensitive
monomers which polymerize upon irradiation in proportion to absorbed dose. These gels
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can then be evaluated in 3 dimensions (3D) by measuring the amount of polymerization.
Several imaging techniques including CT, optical-CT, MRI, and ultrasound can be used
to read the gel dosimeters.
A known limitation of polymer gel dosimeters is that they require extremely low oxygen
concentration, less than 0.01 mg g-1, because oxygen inhibits the radiation induced
polymerization through peroxide formation(59). Therefore, the fabrication and use of
these gels had to be completed in glove boxes to avoid oxygen contamination. In 2001,
Fong et al. proposed Methacrylic and Ascorbic acid in Gelatin Initiated by Copper
(MAGIC) polymer gel, which uses ascorbic acid mixed with copper(II) complex to
utilize the oxygen molecules to support, rather than inhibit, polymerization(59). This
enables fabrication and use of gel dosimeters in normal room air conditions.
In this study, MRI is used to determine the amount which the gel is polymerized from
irradiation. MRI can indirectly determine the gels exposure by measuring the spin-spin
relaxation rate, R2, which increases as the irradiation polymerizes the gel, reducing the
mobility of gel protons(55-57). Unlike conventional clinical T2 weighted images, R2 (R2
= 1/T2) values were used to measure polymerization as R2 values filter out image
inhomogeneity due to inhomogeneous radio-frequency fields (1) and external magnetic
field (1)(59).
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5.2
5.2.1

Materials and Methods
Polymer Gel Fabrication

MAGIC gel, as described by Fong et al. with 9% methacrylic acid concentration, was
used in this study(60). The phantom, a polyethylene cylindrical container, was filled 568
ml of gel and placed into a refrigerator to allow the gel to cool but not completely set.
Five hundred and fifty (550) ± 55 MBq in 10 ml of 90YCl3 solution was slowly injected
while stirring using a long needle to create a heterogeneous distribution. The phantom
was sealed and gently shook to provide for additional mixing.
The change in polymerization, and therefore R2, upon irradiation is based on the chemical
composition of the gel. Therefore, the correlation between dose and R2 values is
established using calibration procedures. The calibration performed in this study used 7
glass vials filled with 20 ml of gel and varying 90Y activity (95.8 – 4.4 MBq). These
calibration vials were sealed and vigorously shaken in order to achieve uniform
concentrations within each vial. The vials were then placed inside a large cylindrical
water phantom for imaging.
Standard MIRD methods were used to determine the absorbed dose to each calibration
vial(61):
Equation 5.1



,
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where  is cumulative activity at the time of imaging, n is the number of particles per
decay, E is the average particle energy,  is the absorbed fraction, and m is the mass of
the gel. Cumulative activity was determined based on the time 90Y had to decay in the
gel prior to the MR scan using the equation:
Equation 5.2



with initial activity,




    

, determined via assay in a Biodex Atomlab 100 dose calibrator.

A 10% uncertainty in the activity measurement was again assumed as described in
chapter 4.
Monte Carlo transportation code MCNPx was used to determine the absorbed
fraction(62). The 90Y electron energy spectrum provided in the Nuclear Regulatory
Commission radiological toolbox was utilized(63). The electron starting position was
chosen at random inside a cylindrical geometry modeled to match the calibration vials
dimensions. Energy deposition throughout the vial was tallied. The MAGIC gel specific
cross-section data was created using the relative elemental weight fractions and density as
provided by Fong et al(60). Additionally, the dose was based on the cumulative activity
decayed at the time of the phantom MR acquisition, and not based on decay over infinity
as used when calculating patient dose maps.
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5.2.2

Imaging Techniques

MR imaging was completed approximately 13 and 18 hours after manufacturing on a
Siemens MAGNETOM TIM trio 3T scanner (Siemens Healthcare Molecular Imaging,
Hoffman Estates, IL, USA), with a 12-echo multiple spin-echo pulse sequence (TR =
5000 ms, TE = 10, 20, …, 110, 120 ms). The calibration vials and phantom were
centered inside a standard head coil. The calibration images had in-plane pixel size of 0.8
X 0.8 mm2 with a slice thickness of 10 mm. The phantom images had in-plane pixel size
of 2 x 2 mm2. These images were later resized using bicubic interpolation in ImageJ to
match the 4 x 4 mm2 pixel size of the PET images. The phantom images had a slice
thickness of 6 mm.
Pixel T2 values were derived using Siemens Syngo MR B17 commercially available
workstation. The reciprocal of the T2 images were inverted in a routine written in IDL
(Interactive Data Language, Research Systems Inc., Boulder, CO, USA) to produce a
relaxation rate (R2) map. Circular regions of interest containing approximately 320
pixels were drawn over the center of the calibration vials to determine the R2 values for
the vials for use in the calibration curve with absorbed dose.
The PET/CT acquisitions were collected in a similar manner as described in previous
chapters, with 10 minute acquisitions corrected for randoms, decay, attenuation, and
normalization and a 5 mm Gaussian filter. Again, acquired data was reconstructed using
Siemen’s iterative reconstruction algorithm TrueX® with 2 iterations, 14 subsets. As
stated in chapter 2, this algorithm includes point spread function spatial recovery which
reduces the reconstruction point spread function (PSF). PET DICOM image arrays were
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post processed in IDL to correct for the 90Y positron branching ratio and to apply the
proper decay corrections. PET images were converted to dose maps similar to the method
described in chapter 4. However, a unique S-kernel was used for the dose conversion
specific to the MAGIC gel, using the chemical composition and density of the MAGIC
gel in place of liver tissue’s values. Additionally, the dose was based on the cumulative
activity decayed at the time of the phantom MR acquisition, and not based on decay over
infinity as described for patient dose maps.

5.2.3

Dose Comparison

MIMVista® software was used to visually register MR and CT phantom images,
allowing for fusion of the MR and PET images. A volume of interest (VOI) was
generated over the entire phantom using the whole body tool over the CT image to
evaluate average dose found throughout the whole phantom. The PSF in the PET image
was measured from a 10 minute acquisition of a 90Y point source (<0.1 mL) placed in the
middle of the PET field of view. The acquisition was reconstructed and corrected using
the same method as the phantom. The MR dose map was convolved with the PET PSF to
allow comparison of similar spatial resolution images.
Sixty (60) voxels located inside the VOI were chosen at random on the CT image
associated with the PET to compare the dose maps voxel by voxel. Dose volume
histograms (DVH) were created with bin sizes of 1 Gy for the VOI. Quantitative gamma
analysis was performed to evaluate DVH agreement as described by Ebert et al(64).
Varying volume-difference ( VR) and dose-to-agreement ( DR) criterion were evaluated
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with gamma () < 1 indicating agreement. PET dose map was used as the reference
image for both MRI and MRI convolved with PSF comparisons.

5.2.4

Statistical Analysis

Calibration vial R2 values were plotted against calculated absorbed dose and fit using a
simple linear regression. The standard deviation of the R2 values was determined for each
calibration vial ROI. Fractional uncertainty in the calibration dose was determined using
the method described by Gear et al (65). The standard deviation observed for uniform
dose values was recorded off the MIMvista VOI.

5.3

Results

The calibration vial dose response curve was well described by a linear function (r2 =
0.966) with a slope and intercept of 0.86 ± 0.040 and -0.038 ± 0.99 with R2 (Figure 5.1).
The average uncertainty in dose based on linear regression was 2.5 Gy. The
corresponding pixel-to-pixel standard deviation in R2 values was 0.75 s-1.
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Figure 5.1 Calibration dose-response curve of MAGIC gel vials. The individaual data
points represent the R2 values with horizontal error bars representing pixel-to-pixel
standard deviations and vertical error bars representing fractional uncertainty based on
mass and activity. The solid line is the fit to the measured data.
The mean absorbed dose to the whole phantom was 5.3 ± 1.8 Gy for the PET based
dosimetry and 5.3 ± 1 Gy for the MRI gel-based dosimetry. Both measurements were
within one standard deviation of the calculated absorbed dose of 5.8 Gy with an
uncertainty of 0.58 Gy.
Table 5.1 Full-width half-maximum (FWHM) of PET point spread function.
Dimension
FWHM (mm)
x
6.0
y
6.1
z
7.3

Coronal slices of the dose maps demonstrate similar dose distribution throughout MR and
PET images (Figure 5.2a, b). However, the MRI dose map demonstrates higher dose
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gradient than the PET map due to the superior spatial resolution in the MRI image. The
measured full width half maximum values of the PET PSF are displayed in table 5.1.
Convolving the MRI dose map with these PSF values results in a resolution similar to
that found in the PET image (Figure 5.2c).

Figure 5.2 Coronal slices of phantom dose maps from a) PET, b) MRI, and c) MRI-PSF
with a window of 0 to 30 and a level of 15 Gy.
Voxel-by-voxel comparison demonstrates the PET dose map generally found lower dose
values than the MRI due to the poorer spatial resolution of the PET image, resulting in
the apparent spreading of activity (Figure 5.3a). However, the MRI convolution with the
PET PSF resulted in a linear, but nosy, relationship between dose values with a slope of
0.97 between the PET and MRI-PSF dose maps (Figure 5.3b). The noise found in the
image presented in chapter 2 can clearly be seen in this comparison.
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Figure 5.3Voxel-by-voxel comparison of the PET image with the a) original MR dose
map and b) MR dose map convolved with the PET PSF
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Figure 5.4DVH for PET and a) MRI and b) MRI-PSF dose maps from whole phantom
VOI shrunk 1 cm to avoid boundary influence. Gamma () value from 3% and 5% dose
and volume acceptance criteria are as shown.
Comparison of DVH curves found poor agreement ( > 1) between the original MRI and
PET dosimetry methods (table 5.2). The average -value was 2.5 at 1% for both VR and
DR criterion (figure 5.4a). Better agreement is reached once the MRI is convolved with
the PET PSF, with an average -value of 0.9 at 1% VR and DR criterion (table 2, figure
5.4b).
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Table 5.2 Percent DVH bins with agreement ( < 1) for varying dose and volume
agreement criterion
PET versus MRI
PET versus MRI-PSF
DR/ VR
1%
3%
5%
10%
1%
3%
5%
10%
1%
42%
67%
76%
95%
61%
100%
100%
100%
44%
68%
83%
98%
71%
100%
100%
100%
3%
5%
50%
77%
97%
98%
88%
100%
100%
100%
10%
58%
95%
97%
98%
88%
100%
100%
100%

5.4

Discussion

This study demonstrates polymer gel dosimetry is a feasible technique to provide 90Y
dosimetry using MRI. With simple linear regression, R2 measurements were able to
predict the phantom’s mean absorbed dose within the 10% uncertainty in total activity.
This is similar to the accuracy found in uniform phantom measurements presented in
chapters 2 and 4.
Unlike the situation when using the uniform concentration phantom, polymer gels enable
the use of high spatial resolution imaging such as MRI. High spatial resolution dose
maps in turn enable an evaluation of the effect of spatial resolution of the imaging system
(acquisition and reconstruction techniques) on dose estimate. The dose map created
through the MRI convolved with the PET PSF was shown to accurately predict and
match the PET-based dose map as shown through voxel-by-voxel and DVH comparison.
Additionally, this study demonstrated that spatial resolution effects dose results
calculated using image based dosimetry methods, specifically lowering the maximum
dose values where distributions occur with large gradients. It is expected the more
uniform the source is, the less profound this effect would be.
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5.5

Conclusions

This study demonstrates the feasibility of using polymer gel dosimetry for verification of
voxel based 90Y dosimetry created using imaging, such as PET/CT. With the use of this
technique, future research can be conducted in optimizing imaging protocols for 90Y
dosimetry in heterogeneous concentrations as found following radioembolization.

80

CHAPTER 6. MONTE CARLO SIMULATION WITH 90Y PET/CT INPUTS
PREDICTS EXTERNAL DOSE RATES SURROUNDING PATIENTS
FOLLOWING RADIOEMBOLIZATION

6.1

Introduction

Historically there has been little concern about external dose rates around patients
following radiotherapy with - emitting isotopes, such as 90Y, due to the short range of
the - particles resulting in low exposure rates outside the patient. However,
bremsstrahlung photons produced by the slowing down of the - particles can result in
exposure to others and should be evaluated. In the United States, the Nuclear Regulatory
Commission (NRC) and agreement states regulate the release of patients who have
received byproduct radionuclide material, such as 90Y, to ensure adequate radiation safety
to members of the public who may be exposed to radiation from patients following
treatment. Pursuant to title 10 of the Code of Federal Regulations (CFR) Part 35.75, or
agreement state equivalent, a hospital may only release a patient if it is not likely that any
other individual could receive a total effective dose equivalent (TEDE) of 5 mSv from
exposure to the released individual. Additionally, the hospital must provide instructions
to the released individual to maintain radiation exposure levels to other individual as low
as is reasonably achievable (ALARA) if the TEDE to any other individual is likely to
exceed 1 mSv.
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10 CFR 20.1003 defines TEDE as the sum of external dose equivalent (EDE) and internal
radiation exposure. As the majority of the 90Y glass microspheres become permanently
lodged in the liver, internal radiation exposure to individuals other than the patient can be
assumed to be negligible(66). Resin microspheres (SIR-spheres®) have trace amounts of
free 90Y on the surface which can lead to small amounts of excretion through urine, but
internal radiation exposure is still expected to be minimal following appropriate
precautions such as washing hands after urination(20). The only concern for internal
radiation exposure following radioembolization would be breast feeding, which is not
considered in this study.
EDE is defined as the sum of the products of the dose equivalent to individual organs and
tissues and the weighting factors applicable to those tissues. Assuming the individual is
exposed to the whole body, the tissue weighting factor becomes 1 and EDE is simplified
to the dose equivalent to the whole body, making EDE equivalent to the historically used
dose term deep dose equivalent (DDE). The recommended equation to calculate DDE
following patient release is:
Equation 6.1

 

 




where DDE is in mSv; Ro is the dose rate at 1 m from the patient in mSv hr-1; Tp is the
physical half-life in days (2.67 days for 90Y); E is the fraction of time a person is
expected to be within a certain distance from the released patient, known as the
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occupancy factor; and r is the distance from the patient in meters. R0 currently is
determined by either survey measurement or the following calculation,
Equation 6.2





,

where  is the bremsstrahlung constant in soft tissue, 1.52 x 10-3 mSv cm-2 MBq-1 hr-1,
and Qo is the administered activity(67). If a survey measurement is used, it is generally
taken at 1 m above the surface of the patient. The occupancy factor and distances are
generally based on the NRC recommended general public scenario, which assumes an
individual is present at 1 m distance from the patient for 6 hours a day (E= 0.25)(68).
More restricted scenarios for caregivers proposed by Siegel et al.(69) are shown in table
6.1.
Table 6.1 Exposure scenerios used to calculate dose to individuals following patient
release
Scenario
Occupancy Factor (E)
Distance (m)
NRC General Public
0.25
1m
Caregiver
0.25
0.3 m
Significant Caregiver
0.5
0.3 m

In a study published by Gulec et al. in 2007, a linear source assumption was
recommended to convert  measured at 1 m to dose rates at distances less than 1 m(70).
This linear source assumption was based on dose measurements provided in the SIRsphere training manual which found doses of 18.8, 9.2, and 1.5 μSv/hr at 0.25, 0.5, and 1
m from a patient who received 2.1 GBq of 90Y during treatment. From these
measurements, the correction factor, based upon a linear dose model assumption, was the
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new distance, expressed in cm, divided by 3. Using this assumption, the DDE can be
estimated using equation 6.3 in scenarios requiring distances shorter than 1 m:
Equation 6.3

 

 



 

Using this equation with the bremsstrahlung constant, 1.52 x 10-3 mSv cm2 MBq-1 hr-1, it
was found that an activity level of at least 14.3 GBq would be required to exceed the
lower limit of 1 mSv using the most restrictive scenario, the significant caregiver. Gulec
et al. stated that the maximum treatment dose is around 9 GB and therefore the regulatory
thresholds are never expected to be met following radioembolization.
However, in a recent study published in 2012 by McCann et al, 15.7% (3/19) of dose
rates found around patents led to a calculated TEDE exceeding the 1 mSv threshold
following TheraSphere® radioembolization assuming the significant caregiver scenario
and using dose rates measured at a distance of 0.3 m instead of 1 m. The highest activity
administered in this study was 5.14 GBq, significantly lower than 14.3 GBq.
It is hypothesized that the difference between the findings of these studies is due to the
method used to estimate dose rate at 0.3 m. Although the linear source assumption may
be correct in some cases, it was believed that the dose rate distributions around patients
will vary and may be dependent on the direction the measurement is taken around a
single patient. Additionally, variation in the distance the bremsstrahlung photons have to
travel to escape the body is believed to change the bremsstrahlung constant.
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In this study, we will demonstrate the feasibility of a new method to determine dose rate,
R0, around patients following radioembolization by incorporating quantitative 90Y PET
images, with associated CT images for shielding, into a MC simulation. The simulated
dose rate results will be used to estimate dose to other individuals who are in close
proximity to patients released from hospitals after radioembolization and evaluate the
applicability of the linear source assumption and the 90Y bremsstrahlung constant.

6.2

Materials and Methods

6.2.1

Image Acquisition

Dose rates around 10 patients were simulated in this study. Only patients with 1 bed
position acquisitions were used to minimize computational resources. PET images were
acquired and reconstructed as described in chapter 4.

6.2.2

Monte Carlo Simulation

MCNP5 was used to simulate the production and transport of bremsstrahlung photons.
MCNP is a general purpose, continuous energy MC radiation transport code developed at
Los Alamos National Laboratory(71). MCNP5 was used due to its repeated structure
feature, allowing CT images to be converted into a heterogeneous hexahedra lattice
structure based on a subgrouping of the tissue. To meet MCNP memory requirements,
CT arrays, originally 512x512, were bilinear resampled to 123x123 using ImageJ(72).
The resampled CT image was then converted to a MCNP input card using an in house
conversion program written in IDL. This program grouped materials into 6 bins based on
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CT Hounsfield units (HU) based on a method validated in DeMarco et al. study (Table
2)(73). Since localized density differences inside the body would have minimal impact
on external dose rates, one density value was used for each material group. Besides lung
tissue, density and weight fractions of each material was gathered from ICRU44(74).
The lung density was set to the mean lung density found in the DeMarco et al. study.
Table 6.2 Tissue groupings based on CT Hounsfield units (HU) for MCNP input
Material HU Numbers
Density [g cm-3]
Air
<-930
0.00120479
Lung
-930:-200
0.35
Fat
-200:-5
0.95
Water
-5:5
1.1
Muscle
5:280
1.05
Bone
280:1000
1.92

Voxel activity from the PET DICOM array was used as the MCNP source term. Using
the in-house conversion program, a point source was created at the center of each PET
voxel with the source probability set to the PET measured activity. A point source was
deemed reasonable to replace voxel volumetric sources (0.4x0.4x0.3mm) to minimize
computational resources since exposure rates were measured outside the body at a
minimum of 0.3 m away.
As described in chapter 4, the low SNR of 90Y leads to high MDA and positive bias
following commercial iterative reconstruction. To limit the effect of the positive bias, a
radiologist defined contour of the treated lobe was used to create a volume of interest
(VOI) where the 90Y microspheres are trapped during the treatment. A threshold was
used to match the VOI activity to the liver to remove the positive bias(75). All PET
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activity measured outside the treated lobe VOI and that found below this threshold was
set to zero before defining the source.
Dose rates were determined at 0.3, 0.5, and 1 m away from the surface of the patients’
body in the anterior and posterior direction, directly above and below the treated lobe.
Additionally, dose rates were determined at the same distances to the sides of the patient.
Locations were selected based on location of the highest activity found in the PET scans.
The patient boundaries were defined on the CT images associated with the PET images.
An energy deposition tally, F6 type, was used to determine the average energy deposited
over a detector with a 1 x 5 cm detector face, with the z-axis (sagittal) having the 5 cm
dimension. This energy deposition was converted to a dose rate through the following
equation:
Equation 6.4



   

     ,

where Ed is the energy deposited in MeV g-1 and A is 90Y activity in the liver in Bq, and t
is time in s.

6.2.3

Dose Rate Verification

Eight (8) dose rate measurements were collected from the first day acquisition of the
phantom described in Chapter 2. The survey was conducted with a Ludlum model 19
microR survey meter. The survey locations were at 0.3 and 1 m in four different
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directions, directly above and below and to the right and left. The phantom DICOM
images were imported into the MCNP input file in a similar manner as a patient data set.

6.3

Results

Phantom simulation results demonstrate the feasibility of using MC simulations with
PET/CT images to predict dose rate measurements for 90Y (Table 6.3). The simulated
phantom dose rates had an average percent error of 5.9±3.5% and 3.3±5.4% for measured
dose rates at 0.3 and 1 m, respectively.
Table 6.3 Measured and simulated dose rate results from phantom acquisition
Dose Rates at 0.3 m (μSv/hr)
Dose rates at 1 m (μSv/hr)
Dose rate
Measured
Simulated
Measured
Simulated
Point
Top
2.5
2.3
0.31
0.31
Bottom
2.9
2.8
0.34
0.33
Left
2.2
2.1
0.24
0.24
Right
2.2
2.0
0.21
0.19

Table 6.4 provides the dose calculated from the simulation dose. As shown, dose rates
were found to be highly variable around the patients, with the maximum dose found
above 1 patient, below 3 patients, and to the right of 6 patients. As expected, in no case
was the highest value on the left side of the patient. As shown in figure 6.1, the maximum
measured dose rate found in the simulation at 1 m from the patient was always higher
than that calculated using the bremsstrahlung constant. The average difference between
the simulated and calculated dose rate was 0.5 ± 0.4 μSv/hr.

88

Maximum dose rate at 1 m (μSv/hr)

Table 6.4 Dose rates at 1 m from patient boundary in 4 directions found through
simulation and calculated using  constant
Dose Rate at 1 m (μSv/hr)
Activity
Patient
(GBq)
Above
Below Right
Left
calculation
1

1.3

0.2

0.3

0.4

0.1

0.2

2

1.6

0.4

0.5

0.8

0.1

0.2

3

1.8

1.4

0.1

1.0

0.2

0.3

4

2.1

0.2

0.3

0.5

0.1

0.3

5

2.1

0.4

0.6

0.4

0.1

0.3

6

2.1

0.4

0.3

0.4

0.1

0.3

7

2.7

0.7

0.9

0.6

0.1

0.4

8

2.7

0.3

0.6

0.6

0.1

0.4

9

3.1

0.7

1.0

1.2

0.2

0.5

10

3.9

1.2

1.5

2.0

0.2

0.6

0.6

0.7

2.5
Dose rate
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 calculated dose at 1 m (μSv/hr)

Figure 6.1 Comparison of the maximum dose rates found through simulation and
calculated using  constant at 1 m from the patient surface
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Using the maximum dose rate found at 1 m from the patient, the average dose was 0.02
+/- 0.01 mSv for the NRC general public scenario, with none of the calculated doses
coming close to the 1 mSv threshold. Additionally, no simulated dose rate was found
that resulted in dose exceeding the 1 mSv threshold for the caregiver scenario and no
cases came close to exceeding the 5 mSv threshold for any dose scenarios. However, 1
dose rate was found to result in a dose exceeding the 1 mSv threshold when the most
restrictive scenario, the significant caregiver, was used. The average significant caregiver
dose was found to be 0.4 +/- 0.2 mSv.
Table 6.5 Dose to other individuals calculated using various scenerios for the 10 patients
analyzed based on dose rates found through the simulation based
Dose (mSv)
Patient
General Caregiver Significant
Public
Caregiver
1

0.01

0.1

0.2

2

0.02

0.1

0.3

3

0.03

0.5

1.0

4

0.01

0.2

0.3

5

0.01

0.2

0.3

6

0.01

0.2

0.3

7

0.02

0.2

0.5

8

0.01

0.2

0.4

9

0.03

0.2

0.3

10

0.05

0.2

0.5

90

Figure 6.2 Simulated dose rates found at a) 0.3 and b) 0.5 m compared with calculated
dose rates determined using the linear assumption correction factor with the dose rate
calculated at 1 m using the bremsstrahlung constant. Simulated dose rates at c) 0.3 and d)
0.5 m compared with the dose rates calculated using the linear assumption correction
factor with the simulated dose rates found at 1 m.
6.4

Discussion

This study demonstrates PET/CT DICOM images can be used as inputs into a MCNP
simulation to estimate dose rates surrounding a patient following 90Y radioembolization.
The MCNP simulation provides dose estimates at any location around the patient,
including underneath a patient, which may be difficult to do by survey measurements
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immediately following radioembolization procedures because patients need to remain in a
laying position for approximately 6 hours.
The simulated doses around the patient demonstrated that the linear dose rate assumption
and bremsstrahlung constant do not provide conservative estimates for the dose rates
surrounding patients in the majority of instances. Therefore, this study provides evidence
that measurements, either through survey or simulation, should be collected at all
locations which DDE is to be determined when deciding whether or not to provide patient
instructions as required per regulations. As dose rates were found in this study to
produce DDE close and sometimes greater than 1 mSv in some situations, it is
recommended that patients receive instructions to keep exposure to their caregivers and
family members ALARA. However, as the DDE was not shown to exceed or approach
the 5 mSv value, this study provides additional support that dose rates surrounding
patients following radioembolization should not prohibit patient release.
The simulation values demonstrate that the highest dose rate is not always above the
patient. This study showed that the dose rates can be highly variable in different
directions around the patient due to the distribution of the 90Y and tissue shielding.
Future use of the simulation could allow for patient specific instructions detailing the best
locations which their caregivers or family members should be while in close proximity to
the patient to maintain doses ALARA.
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6.5

Conclusion

This study demonstrated the feasibility of using 90Y PET/CT images as input into a MC
simulation to determine dose rates surrounding a patient following radioembolization.
Through evaluation of a small group of patients, the simulated dose rates clearly showed
the previously suggested linear source assumption and bremsstrahlung constant should
not be used to conservatively calculate dose to other individuals around the patient
following treatment. Although the simulated dose values further demonstrated dose rates
surrounding patients are unlikely to exceed the 5 mSv threshold for patient release, this
study did show instructions may be necessary prior to release of some patients. In
addition, this study demonstrated the usefulness of using imaging results as input data
into MC simulations to generate detailed patient specific external radiation exposure
rates. The external exposure rate information will facilitate the development of caregiver
instructions in order to keep doses to other individuals ALARA.
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CHAPTER 7. PATIENT RESULTS FROM 90Y PET/CT DOSE MAPS

7.1

Introduction

As stated in chapter 1, historically there have been no means to determine the
microsphere distribution found in the liver following radioembolization and gross
assumptions, such as assuming uniform lobe distribution, are used to determine
dosimetry. One such assumption used is to assume uniform distribution across the
treated lobe, which is known to be false as one of the reasons radioembolization is so
successful is due to the preferential targeting of tumor volume. The following section
provides a small portion of patient dosimetry results found with the 90Y PET/CT images
collected at IU health downtown university hospital, demonstrating the use to provide
patient specific dosimetry for future research and clinical use.

7.2

Materials and Methods

The patient images described in chapter 4 were contoured and aligned using MIM
software by a radiologist at IU Health Downtown hospital so dose results to the normal
liver parenchyma and tumors greater than 1 cm could be analyzed. In studies with large
necrotic centers, the tumors were contoured to differentiate between viable and nonviable tumor volumes. Healthy normal tissue parenchymal contours were constructed by
removing tumor volumes from the treated lobe contours. Contour dose, volume, and
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DVHs were gathered from the dose maps using MIM. These were compared against the
empirical dose calculated using the TheraSphere package insert dosimetric equation,
Equation 7.1




,

where A is activity in GBq and m is the mass of the treated lobe, determined based on the
volume of the treated lobe contour in MIM and converted using liver density of 1.03
g/ml.
As described in Chapter 2, positive bias is present in these images when voxels contain
less than the MDC of 1 MBq/ml. Conservatively assuming all energy from 1 MBq of 90Y
is deposited over the 1 ml, the MDC was converted to dose of 48.4 Gy using the
following equation:
Equation 7.2



   


,

where A is the activity 1 MBq and m is the mass of the liver for 1 ml, which is 1.03 g.
Since positive bias was observed only at concentrations below the MDC, the DVH curve
was analyzed for doses only greater than 48.4 Gy.

7.3

Results

The mean percent difference between measured tumor and prescribed dose was 9.7 +/94.6%, with 79 of the 111 lesions having calculated dose exceeding the prescribed. The
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mean percent difference between calculated parenchyma and prescribed doses was 10.5% +/- 19.4%, with 8 of the 63 studies having calculated dose exceeding the
prescribed and average patient tumor doses.
On a voxel level, the average of 37% +/- 14.8 of parenchymal voxels had measured dose
exceeding the prescribed calculated using equation 7.1. On average, 77% of the
parenchymal voxels (SE ± 2.1%) received greater than 50 Gy. Additionally, 35% (SE ±
3.0%) received greater than 100 Gy, 15% (SE ± 5.2%) received greater than 150 Gy, and
6% (SE ± 8.5%) received greater than 200 Gy(76).

7.4

Patient Result Conclusions

These patient results demonstrate the need to determine microsphere distribution
following radioembolization as the assumption of uniform dose is shown to be false.
These results show that in the majority of treatments, the lesion volume received higher
dose than the parenchymal volume. However, 12.7% (8/63) the parenchyma was found
to receive a higher average dose as compared to the tumor volume. With future research,
as described below, the dosimetry information provided by these PET dose maps might
be able to predict tumor response and complication rates on a patient specific basis.
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CHAPTER 8. CONCLUSIONS AND FUTURE WORK

8.1

Summary

Radioembolization is a novel therapy used in treating liver cancers, such as HCC,
which utilizes the livers unique blood supply to deliver 90Y microspheres. As the
microspheres travel from the injection point in the hepatic artery, they distribute in a
heterogeneous fashion as they become trapped in the liver’s microvasculature,
resulting in a heterogeneous liver dose. The therapeutic objective is to have the
majority of the 90Y microspheres deposit inside or close to the tumors, resulting in a
high dose to tumors while sparing normal, radiation sensitive, liver tissue. The exact
distribution and dosimetry is difficult to predict without knowledge of individual
patient’s specific blood supply and microsphere distribution. Therefore, gross
assumptions, such as uniform distribution of the microspheres, have been made in
order to make simple dosimetry estimates.
In 2009, PET imaging was shown to be a feasible method for displaying patient
specific microsphere distribution following radioembolization.

The very small

internal pair production rate of 90Y and the large doses used in the therapy provides
sufficient signal for the generation of PET images. Following the original report,
numerous studied have been published demonstrating the feasibility of using PET to
quantitatively measure the 90Y activity (28-30) and dose (32, 33). However,
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few studies have carefully evaluated the quantitative limitations of 90Y PET
associated with the unique decay characteristics of this radionuclide. This study was
conducted to evaluate the 90Y signal and the accuracy of the 90Y PET images and
dosimetry using various PET reconstruction techniques and gel dosimetry to further
advance the use of PET imaging for patient specific, intra-organ dosimetry following
radioembolization. The summary of the specific aims of this work are provided
below.
1)

Evaluate the effects various reconstructions algorithms have on the accuracy and
limitations of 90Y PET/CT imaging.
As demonstrated in Chapter 2, the parameters used in image reconstruction
substantially affect the accuracy and noise of 90Y PET/CT imaging. Due to the
unique low signal, two commonly used reconstruction techniques in quantitative
reconstruction were found to lead to reduced accuracy. First, smoothing random
sinograms, which is generally desired to reduce variance in random counts, was
found to underestimate 90Y activity likely due to inadequate random correction in
the sinogram tails leading to erroneously high scatter corrections. Second, closed
form DiFT reconstruction led to minimum detectable concentration (MDC)
above which is generally found in the treated lobe following radioembolization
due to the reconstruction’s inability to reduce noise. This study determined the
optimal reconstruction protocol for the Siemens® Biograph 64 PET/CT for 90Y
is 2i14s using commercial TrueX iterative reconstruction to provide a balance
between MDC limitations, quantitative accuracy, and SNR.
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2)

Determine origin of 90Y PET coincident count signal and noise to support
appropriate reconstruction techniques.
Through use of a GATE model this study showed the origin of the 90Y
coincidence counts on the Siemens® Biograph TruePoint 64 PET/CT. This
study demonstrated the extremely poor SNR assoicated with 90Y imaging, even
at concentrations used in therapy. Unlike imaging with higher positron emission
rates, the random coincidence noise was shown to increase linearly with activity.
This increase in random coincidence counts was found to be due to coincedence
counts assoiciated with one photon from bremsstrhalung and one count from
176

3)

Lu.

Evaluate the effect of positive bias observed in 90Y PET/CT using standard
clinical iterative algorithm techniques for reconstruction following sinogram
truncation.
As demonstrated in the previous aim, 90Y has extremely poor counting statistics.
This led to a positive bias where the concentration is less than the MDC due to
truncation of negative sinogram ray-bin values during reconstruction. This study
demonstrated that this positive bias did not affect image accuracy in areas where
concentration was above the MDC, which is generally the case in most tumors.
However, due to the heterogeneous distribution across the treated lobe, it was
shown that most patients had large areas of the parenchyma where the
concentration was below the MDC, resulting in erroneously high PET activity
and dose results for the parenchymal region. Therefore, this study demonstrated
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that while PET images may be used to determine tumor dose, care must be taken
when analyzing dose to regions with low concentration.
4)

Validate 90Y PET/CT dose maps created using a standard S-kernel using gel
dosimetry.
This study demonstrated MAGIC polymer gel dosimetry can feasible provide a
validation method for 90Y heterogeneous dosimetry using MRI. Through voxelby-voxel and DVH comparison with MRI dose map convolved with the PET
PSF to match spatial resolution, the gel dosimetry demonstrated that 90Y PET/CT
imaging provide accurate, but noisy, dose maps using standard S-kernel
convolution. However, the comparison of the original MRI and PET/CT dose
maps demonstrated the limitations of the PET/CT dose maps due to spatial
resolution leading to the spreading of the dose values, reducing the maximum
dose measurement, in areas where 90Y activity is highly heterogeneous.

5)

Use PET/CT 90Y activity distribution maps to verify line source assumption used
in patient release surveys.
In addition to displaying internal dosimetry, 90Y PET/CT images were found to
feasibly provide dose rates surrounding a patient following radioembolization by
being used as input into a MC simulation. Through use of a phantom, the PET
images where shown to have a doses rate accuracy of 10%. In line with previous
studies, the simulation results demonstrated that dose rates surrounding patients
are unlikely to exceed the 5 mSv threshold for patient release. This study
provided an additional use for 90Y PET/CT images as it demonstrated that
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imaging could be used to create patient-specific dose rate maps around patients
following radioembolization, which in turn would enable the provision of better
instructions to keep doses to other individuals ALARA.

8.2

Future Work

As shown throughout this work, the small positron emission from 90Y allows for
PET/CT imaging to provide distribution maps and dosimetry following
radioembolization. As demonstrated in chapter 2, careful consideration is needed to
optimize acquisition and reconstruction protocols for 90Y imaging due to the very
small true signal compared to random noise. This work demonstrated TrueX iterative
algorithm using 2 iterations and 14 subsets following net acquisition with DRCC was
the optimal protocol to balance image accuracy and noise for the Siemens® Biograph
64 TruePoint PET/CT system. As 90Y has an extremely small PET signal, small
differences in scanner geometries, crystal materials and manufacturer correction and
reconstruction algorithms, which generally do not cause large changes while imaging
typical PET isotopes, could have large effects in 90Y imaging. Therefore, an
evaluation should be completed for each type of PET scanner to determine an optimal
reconstruction protocol prior to conducting 90Y PET/CT imaging for quantification
purposes.
With a known source distribution there is significant potential to enhance
radioembolization treatments. As stated in the introduction, current knowledge of
intra-liver dosimetry is very limited. As a result, there is no method to predict tumor
response following treatment. However, with the use of post therapy imaging, studies
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are starting to evaluate whether dose can predict tumor response. Tumor response
from our patient population was analyzed with our PET dose maps by a radiologist
where he found that the fraction response by the tumors improved drastically when
the tumors received greater than 150 Gy and that complete response (as measured
using mRECIST criteria) occurs 90% of the time when the whole tumor received 150
Gy, 75% of the tumor received 200 Gy, or 51% of the tumor received 250 Gy(77).
Unfortunately, tumor response is likely controlled by many variables, such as size of
the tumor, presence of necrotic volume, and blood flow, resulting in differences in
how tumors respond. Therefore, future research is necessary to enable treatment
planning - on a patient specific basis.
Additionally, severe complications, such as radioembolization induced liver disease
(ReILD) described in the introduction, does occur following treatment in some
patients. As radiation induced damage to the liver depends on the amount of
radiation normal, healthy tissue receives, without patient specific dosimetry it is
difficult to predict which patients are likely to have complications. With PET dose
maps, it may be possible to determine the probability which ReILD might occur.
Additionally, future studies could determine if the probability of complications is
different from external beam radiotherapy. It is currently theorized that the liver is
withstanding the higher dose used in radioembolization treatment due to several
factors including embolization causing lower oxygen concentrations for “setting” D
damage, exposure being received at lower dose rates allowing for repair mechanisms,
and dose distribution resulting in sparing of significant volume of healthy tissue in
radioembolization as compared to external beam treatments.
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Unfortunately, tolerance doses of the whole liver found in studies conducted using
external beam therapy are lower than 50 Gy, the approximate minimum dose that can
accurately be measured due to the high image MDC of approximately 1 MBq/ml.
Therefore, comparison of healthy liver response for whole liver exposures could not
be completed unless PET SNR is increased. However, as radioembolization therapies
exposure is localized, as seen from patient results in chapter 4, the fractional volume
of healthy tissue which is expected to be exposed to doses greater than 50 Gy is
generally smaller than the entire liver. As has been shown through external beam
therapy studies, the smaller the portion of the liver exposed, the higher the tolerance
dose. For example, if only two-thirds of the liver is exposed, the tolerance dose raises
to 60 Gy for patients being treated for HCC(78). Therefore, it is believed that 90Y
PET images discussed in this work could be used to compare tolerance doses between
radioembolization and external beam therapy.
In addition to using 90Y PET to predict outcomes from treatments, it could also be
used to support future research to determine if radioembolization treatment planning
is possible. As stated in chapter 1, a 99mTc-MAA SPECT is taken approximately 2
weeks before treatment to grossly estimate where the microspheres will deposit.
However, without post therapy images demonstrating where the microspheres truly
deposit, it is uncertain if the MAA actually deposit in a similar manner as the
microspheres. With the post therapy PET images, correlation between the
distributions could be determined. Additionally, factors such as catheter tip position
and injection flow could be evaluated to determine if they effect the correlation.
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MAA and microspheres distribution may not correlate due to differences in size and
density even if they are injected in the exact same manner. Unfortunately, due to the
PET limitation of a 1 MBq/ml MDC, a diagnostic scan using current PET
reconstruction and correction protocols would not be possible using the current 90Y
microspheres. Therefore, future work would be necessary to either increase the signal
or decrease the noise in the acquisition before microsphere distribution could be
determined using diagnostic activity. As shown in chapter 3, much of the
coincidence count noise arises from the natural radioactivity in the Lu based crystals.
Therefore, future studies could be used to evaluate whether PET machines with nonLu based crystals, such as BGO, have better SNR resulting in lower MDC 90Y PET.
However, LSO crystals are generally used due to their high sensitivity, so it is
uncertain if the reduced random counts would result in significantly better SNR and
therefore images.
It is therefore believed that increasing the signal may be a better option to increase
90

Y PET SNR. One possible technique which may increase the microsphere signal is

to tag or mix the microspheres with a radioisotope with a larger fraction of positron
emission, like 18F. This would allow for diagnostic scan using microspheres with the
same characteristics as used during treatment to predict the distribution of the 90Y
microspheres during radioembolization. The current 90Y post therapy PET could then
be used to verify that diagnostic and therapy distributions match. If they were shown
to match, the diagnostic images could be changed to dose predictions, allowing for
patient specific activity planning. Treatment planning could then balance probability
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of successful tumor response with possible complications enhancing the
effectiveness, and the safety, of 90Y microsphere radioembolization.
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